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Abstract
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Background and Aim: Abnormalities in target organ sensitivity to PTH, PTH circadian 
rhythm and phospho-calcium metabolism contribute to the development of osteoporosis in 
adult growth hormone deficiency (AGHD) and growth hormone (GH) replacement therapy 
increases bone turnover and BMD by restoring PTH sensitivity and circadian rhythm. As 
AGHD has phenotypical features similar' to those of advancing age, the studies in this thesis 
aimed to investigate PTH sensitivity and rhythm in men and women of different age groups 
and bone mineral densities (BMD) to understand the possible impact of these mechanisms on 
age related osteoporosis. The effects of GH administration on PTH sensitivity, PTH rhythm 
and bone mineral metabolism were also studied in older postmenopausal women with 
osteoporosis. The relationship between the circadian rhythm of PTH, osteoprotegerin (OPG), 
a regulator of osteoclast activity, and type I collagen C-telopeptide (PCTX), a marker of bone 
resorption, was also studied.
Methods: Subjects were hospitalized for 25 h during study visits and half-hourly blood and 
3-h urine samples were collected. PTH, calcium, phosphate, nephrogenous cyclic AMP, 
pCTX, procollagen type I amino-terminal propeptide, and 1,25-dihydroxyvitamin D were 
measured. Circadian rhythm analysis was performed using Chronolab 3.0 and Student's t-test 
and general linear model ANOVAs for repeated measures were used where appropriate.
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Results: Postmenopausal women demonstrate decreased target-organ sensitivity to PTH and 
abnormal PTH circadian rhythm when compared with younger premenopausal women with 
more pronounced abnormality in postmenopausal women with low BMD. Older men with 
normal and low BMD demonstrated decreased PTH sensitivity compared to younger men but 
PTH rhythm abnormality was only observed in older men with low BMD. IGF-1 
concentrations were lower in older postmenopausal with low BMD and GH administration 
resulted in an increase in IGF-1 with improvement in PTH sensitivity, restoration of PTH 
circadian rhythm and improved bone mineral metabolism. Significant circadian rhythms were 
observed for PTH, OPG and (3CTX. There was loss of the normal PTH rhythm with a 
sustained increase in PTH concentration overnight in postmenopausal women. There was a 
corresponding, greater percent decrease in OPG secretion in the postmenopausal women and 
a corresponding, higher nocturnal increase in (3CTX.
Conclusions: Abnormalities in PTH sensitivity and rhythm are present in older men and 
women with low BMD. These abnormalities are related to the age related decline in IGF-1 
and can be corrected by the admisnitration of GH. OPG has a circadian rhythm and the 
catabolic effects of the abnormal PTH rhythm in older postmenopausal women may be 
mediated by corresponding abnormalities in OPG rhythm. The findings add a further 
dimension to the complex regulation of bone mineral metabolism and the changes that occur 
with age and also elucidate the mechanisms by which GH exerts its previously demonstrated 
anabolic effects on bone.
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Chapter 1
Introduction and Literature Review
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1.1. Osteoporosis
1.1.1. Introduction
In 1994, the World Health Organisation (WHO) Working Group defined osteoporosis based 
on measurement of BMD (BMD) using dual-energy X-ray absorptiometry (DXA). For 
epidemiological purposes severity of bone loss was reported using T and Z-scores (1). 
However, bone strength is affected, not just by bone density but by bone quality as well and 
osteoporosis is characterised by both low bone mass affecting bone density as well as micro- 
architectural deterioration of bone tissue affecting bone quality. The consequence of these 
changes is an increase in bone fragility and susceptibility to fracture. In 2000, the National 
Institutes of Health (NIH) Consensus Development Panel developed a clinical definition of 
osteoporosis, defining osteoporosis as a progressive, systemic, skeletal disorder characterised 
by compromised bone strength predisposing a person to an increased risk of fracture (2). 
This definition took into consideration bone density, bone quality and concomitant risk 
factors that contribute to fracture risk. Thus, over the year's, the focus of diagnosis, risk 
stratification, prophylaxis and treatment of osteoporosis has shifted. The focus is no longer 
limited to bone density alone. Based on more in-depth understanding of bone cellular* and 
bone metabolic changes, this focus now encompasses other factors that underlie and 
contribute to the development of osteoporosis and fracture risk in different groups of 
individuals.
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1.1.2. Aetiology and Risk Factors
The aetiology of osteoporosis is multi-factorial with multiple risk factors having been 
identified. These include age, muscle mass, body weight, the level of peak bone mass prior to 
the onset of age-related bone loss, behavioural factors such as decreased physical activity, 
smoking, alcohol consumption, low intake of important nutrients, consumption of various 
drugs, diseases such as malabsorption, anorexia nervosa and renal hypercalciuria. The 
FRAX® tool, developed by the WHO to evaluate fracture risk of patients is based on 
individual patient models that integrate the risks associated with clinical risk factors as well 
as BMD (BMD) at the femoral neck (FN). The FRAX® models have been developed from 
studying population-based cohorts from Europe, North America, Asia and Australia. The 
FRAX® algorithms give the 10-year probability of hip fracture and the 10-year probability of 
a major osteoporotic fracture (clinical spine, forearm, hip or shoulder fracture). The risk 
factors identified as being important to risk contribution, excluding secondary causes of 
osteoporosis, include age, gender, body mass index, a prior fragility fracture, parental history 
of hip fracture, current tobacco smoking and alcohol consumption of 3 or more units per day. 
The FRAX® tool is however limited by the lack of adequate international data on other 
factors that may be contributory to risk (e.g. biochemical markers of bone turnover, growth 
factors), the complexity of practically quantifying certain risk factors (e.g. physical exercise). 
Endocrine factors including sex steroids, parathyroid hormone (PTH), GH and IGF-1 have, in 
epidemiological studies, been related with fracture risk and do contribute significantly to the 
development of osteoporosis via different, complex and often interlinked mechanisms at 
different stages of bone loss that are still not fully understood and warrant further 
investigation.
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1.1.3. Types of Osteoporosis
Primary osteoporosis is the most common form of osteoporosis and is diagnosed when other 
disorders known to cause osteoporosis are not present. Primary osteoporosis has been 
classified according to age groups as juvenile osteoporosis when it affects prepubescent boys 
and girls, idiopathic osteoporosis in young adults when the cause is not related to another 
disease, postmenopausal osteoporosis when it occurs in women within 15-20 years after 
menopause and age-related, or senile, osteoporosis in the elderly. Primary or involutional 
osteoporosis in these individuals of different ages, in which no underlying cause can be 
identified, is believed to develop as a result of excessive bone loss caused by varying but 
more marked expression of what would be considered age-related changes in bone. 
Secondary osteoporosis, on the other hand is defined by an identified underlying cause.
Others have suggested that two subtypes of primary osteoporosis can be distinguished in 
aging women: (i) postmenopausal osteoporosis and (ii) age-related or senile osteoporosis (3). 
Arbitrarily, postmenopausal osteoporosis is said to affect women who are postmenopausal 
but younger than 70 year’s. These women are said to have type I or postmenopausal 
osteoporosis if excessive bone loss that meets WHO criteria occurs within 15-20 years after 
menopause. This type I osteoporosis is characterized by increased bone resorption due to 
osteoclastic activity and is generally believed to be related to oestrogen deficiency and is 
associated with preferential loss of trabecular' bone making them prone to vertebral crush 
fractures and fractures of the distal radius. Age-related osteoporosis, also called senile or type 
II osteoporosis occurs when there is excessive bone loss manifested after age 70 years in both 
women and men. Type II osteoporosis results from normal aging and is associated with a 
steady loss of both cortical and trabecular' bone mass each year'. Age-related bone loss begins
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at age 35-40 years when the balance shifts to favour resorption and the skeleton begins to lose 
bone mass. Hip and vertebral fractures are most common in this type of osteoporosis. In 
addition to vertebral crush fractures, vertebral wedge fractures with gradual deformation of 
the spine are also seen.
Bone Loss
I. 2.1. Patterns of Bone Loss
The prevalence of osteoporosis increases with age in both men and women as bone mineral 
loss is a predictable accompaniment of aging in both women and men. After closure of the 
endochondral growth plate, bone mass increases by radial growth until peak skeletal mass is 
achieved between 20 and 25 year's of age as reported in the majority of studies. Studies also 
highlight that the age of attainment of peak bone mass is bone site specific (4-9).
Several anatomical studies (10, 11) and most cross-sectional densitometric studies (12-14) 
have demonstrated that after a transient period of stability, the slow phase of age related bone 
loss begins. This slow phase involves a linear, continued, steady, age-related annual loss of 
skeletal mass of about 0.5-1.0% in women and 0.3% in men that continues into old age (10,
II, 15). Latterly, however, the pattern of age related bone loss varies between genders and a 
biphasic pattern of bone loss has been identified in women, who undergo an accelerated 
transient phase of bone loss superimposed on the slow continuous phase, whereas men 
undergo only the protracted slow continuous phase (3, 16). It is this slow pattern of bone loss 
that results in what is called by some as type 2 or senile osteoporosis. The accelerated phase 
in women begins at menopause, involves predominantly cancellous bone loss and has been
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attributed to the cessation of ovarian function. Oestrogen restrains bone turnover and when 
this restraint is lost at menopause, overall bone turnover increases and resorption increases 
more than formation. As the rapid bone loss phase subsides, there is an absolute increase in 
bone resorption and a relative decrease in bone formation involving equal losses of cortical 
and cancellous bone. The accelerated phase of bone loss decreases over 5-10 years to merge 
again with the slow phase that continues indefinitely. A decrease in BMD into the 
osteoporotic range during the immediate postmenopausal period as a result of the increased 
bone resorption is called by some as type 1 osteoporosis.
It has also been suggested that even within a population of postmenopausal women with 
increased bone resorption there are “fast” losers and “slow” losers of bone. Some studies 
have suggested that the “fast” loss of bone is only transient but most agree that a higher bone 
resorption rate in the “fast” losers increases their risk of fractures independent of BMD. The 
reasons why some women lose bone faster than others is still unexplained. The difference in 
the rate of loss may be the reason why some postmenopausal women develop osteoporosis 
and others don’t. Also, “fast” losers benefit more from antfresorptive therapy than “slow” 
losers. Thus an understanding of the pattern of bone loss in individuals is of importance from 
a clinical perspective and the easier assessment of this “fast” loss with reliable biochemical 
markers of bone resorption allows risk stratification and choice of appropriate therapy.
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1.2.2. Mechanisms of Bone Loss
The adult skeleton is in a dynamic state, continually being broken down and reformed by the 
coordinated actions of osteoclasts and osteoblasts on bone surfaces and in haversian systems. 
This turnover or remodeling of bone occurs in focal and discrete packets or units, known as 
bone remodeling units or bone multicellular units, throughout the skeleton. The sequence of 
bone turnover involves activation of osteoclast precursors, and then osteoclastic bone 
resorption, followed by osteoblastic bone formation to repair the defect, known as the 
“coupling phenomenon”. In the steady state, this coupling of bone resorption and formation 
maintains bone mass.
The rate of bone remodeling is to a large extent dependent on the frequency of osteoclast 
activation which is the initial step in the remodeling sequence and occurs in specific focal 
sites by mechanisms that are still not understood. One possibility is that osteoclast precursors 
recognise a change in the mechanical properties of aging bone, which requires replacement 
with new bone for optimal structural integrity. This theoretical possibility could occur 
because other cells, such as immune cells or osteocytes, recognise a change in the bone 
surface and send signals to osteoclasts to activate them. However, the initial trigger for such 
activation of immune cells is unknown. The resorptive phase of the remodeling process has 
been estimated to last 10 days. This is followed by repair of the resorption pit by osteoblasts, 
a process that takes approximately 3 months resulting in new bone formation. Following 
osteoclast formation and activation, the specific cellular events that occur at sites of 
osteoclast resorption include osteoclast apoptosis. This is then followed by a series of 
sequential changes in cells in the osteoblast lineage, including osteoblast chemotaxis,
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proliferation and differentiation, which in turn are followed by formation of mineralised bone 
and cessation of osteoblast activity.
In normal young adults, the resorption and formation phases are tightly coupled and bone 
mass is maintained. Bone loss implies an uncoupling of the phases of bone remodeling with a 
relative or absolute increase in resorption over formation. When this uncoupling occurs, an 
increase in bone turnover leads to increased bone loss. The slow and accelerated phases of 
bone loss are associated with two different abnormalities of bone remodeling (15, 17). The 
slow age-dependent phase results mainly from impaired bone formation; osteoclasts construct 
resorption cavities of normal depth, or even decreased depth (18), but osteoblasts fail to refill 
them completely. It has been suggested that this is a combination of various factors including
(i) decreased osteoblast and osteoclast numbers resulting in a decreased bone formation rate;
(ii) increased reactive oxygen species resulting in decreased glutathione reductase activity, a 
corresponding increase in the phosphorylation of p53 and p66(shc) (two key components of a 
signaling cascade that are activated by reactive oxygen species and influences apoptosis and 
life span) and a consequent increase in osteoblast and osteocyte apoptosis (19, 20). The 
accelerated phase of bone loss occurring in women soon after the menopause is associated 
with a high rate of bone turnover and increased numbers of osteoclasts, each creating a 
deeper resorption cavity (18, 21).
The cellular' and humoral mechanisms responsible for mediating bone turnover and the 
coupling process are still not completely clear' and neither are the mechanisms responsible for 
the altered bone turnover and the uncoupling that occurs in age-related bone loss contributing 
possibly to the pathophysiology of the development of age-related osteoporosis. Many
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hormones and factors with differing mechanisms of action have been shown to stimulate 
osteoclast activity. PTH stimulates differentiation of committed progenitors to fuse to form 
mature multinucleated osteoclasts and also activates preformed osteoclasts to resorb bone. 
l,25(OH)2D is a potent stimulator of osteoclastic bone resorption and like PTH stimulates 
osteoclast progenitors to differentiate and fuse (22). It also activates mature preformed 
osteoclasts, possibly by a mechanism similar to that of PTH. It had also previously been 
proposed that activation of osteoclasts may also be indirect and mediated through cells in the 
osteoblast lineage (23) as osteoblasts express receptors for various growth factors, cytokines, 
oestrogen, PTH and vitamin D. Bone is also a major reservoir of IGF-1 and in vitro studies 
have suggested that IGF-1 secreted by local stromal cells such as osteoblasts, may mediate 
GH effect on osteoclast activity (24, 25). The predominant messenger by which osteoblasts 
talk to osteoclasts in response to various stimuli has been identified as receptor activator of 
nuclear' factor-kappa B ligand (RANKL), which is produced by osteoblasts and exerts its 
effects through binding to its receptor (RANK) on osteoclast precursor cells. The binding 
results in activation of osteoclasts. Osteoblasts also produce osteoprotegerin (OPG), a potent 
inhibitor of osteoclast formation and a decoy receptor for RANK. The relative ratio of OPG 
and RANK ligand in the bone marrow microenvironment determines the number of active 
osteoclasts, bone resorption rate, and bone mass. IGF-1 has been shown to alter OPG 
production, suggesting a role in maintaining the cross talk between osteoblasts and 
osteoclasts and the coupling phenomenon (26). Recently, the involvement of osteocytes in 
osteoclastogenesis and bone resorption was reported using conditional knockout mice of J3- 
catenin by Dmpl-Cre, which resulted in enhanced bone resorption, and conditional knockout 
mice of receptor activator of NF-kB ligand (Rankl) by Dmpl-Cre, which resulted in 
osteopetrosis. Using a newly established method for the isolation of high purity osteocytes 
from bone matrix, it has also been demonstrated that osteocytes express a much higher
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amount of RANKL and have a much greater capacity to support osteoclastogenesis than 
osteoblasts and bone marrow stromal cells, thus suggesting that osteocytes may be the more 
relevant cell at the initiation of the bone remodeling through regulation of osteoclastogenesis 
(27-31).
Several theories have also been proposed to account for coupling of resorption to formation. 
Many workers have favoured the notion that coupling is Immorally mediated and that an 
osteoblast-stimulating factor, such as GH, IGF-1, transforming growth factor-p, skeletal 
growth factor, bone-derived growth factor or macrophage derived growth factor is released 
from bone matrix during the process of osteoclastic bone resorption and the stimulation of 
osteoblast activity leads to new bone formation (32). Systemic or local age related decline or 
defects in GH, IGF-1 and these other growth factors may result in impaired osteoblast 
activity leading to uncoupling of bone formation from resorption resulting in age related bone 
loss. A variation in this humoral concept is that the factor that stimulates resorption also acts 
directly on osteoblasts to cause their activation and subsequent new bone formation (33). This 
notion suggests that coupling does not involve sequential signals released during the process 
of bone remodeling, but rather the factors that work through the GP-130 signal-transduction 
mechanism are responsible for simultaneous stimulation of osteoclast and osteoblast lineages. 
An alternative to the humoral hypothesis for coupling is that because osteoblasts normally 
line bone surfaces, once the phase of osteoclastic resorption is over and the osteoclasts 
disappear from the resorption site, osteoblasts and their precursors repopulate the resorption 
site and merely reline the bone surface, thus, repairing the resorption defect without the 
involvement of a humoral mediator.
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1.3* Bone Metabolism
1.3.1. PTH and Bone
PTH plays an important role in bone remodeling (34) and has complex but only partially 
understood actions on bone that requires the presence of and often direct contact with several 
different speciahsed cell types (35). PTH has also been shown to have both catabolic and 
anabolic effects on bone (36, 37).
1.3.1.1. End organ effects of PTH
The effects of PTH on bone are mediated via direct effects on PTH receptors in bone and 
indirectly through regulation of the vitamin-D and phospho-calcium metabolism via receptors 
in the kidney (38). The PTH receptors in bone mediate the regulation of chondrocyte and 
osteoclast proliferation and differentiation (39), whereas, in the kidneys activate the 
mitochondrial vitamin D 1- a hydroxylase leading to increased serum l,25(OH)2D, which in 
turn is an inducer of intestinal Ca absorption as well as bone resorption (40).
PTH acts through guanine nucleotide-binding regulatory protein (G protein) receptors that are 
present on the cells of the target organs, and results in the stimulation of at least 2 different 
intracellular signal transduction pathways (41). Activation of the Gs component of the 
receptor results in stimulation of the adenylate cyclase / cyclic adenosine monophosphate 
(cAMP) pathway. Activation of the Gq component leads to the production of phospholipase 
C (PLC). Binding of PTH to its receptor leads to activation of PLC with the subsequent 
hydrolysis of phosphatidylinositol 4,5-bisphosphate to inositol 1,4,5-trisphosphate (IP3) and
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diacylglycerol (DAG), IPS generation leads to the release of intracellular Ca stores, which 
produces an increase in the intracellular Ca concentration (41, 42). The cellular functions 
regulated by each pathway after PTH receptor binding, together with the inter-pathway 
synergy, are not fully explained.
The second messenger cAMP mediates the action of PTH at target organs, including the bone 
turnover in the skeleton and regulation of Ca and phosphate (P04) excretion in the kidney 
(43-46). Plasma cAMP (PcAMP) can be quantified but is a poor measure of PTH activity as 
cAMP also acts as a second messenger for other systems (47). PcAMP is excreted by a 
process of simple glomerular' filtration; to this filtered load of the nucleotide is added a 
quantity of cAMP formed de novo in the kidney, nephrogenous cAMP (NcAMP). NcAMP is 
the only pool of the nucleotide easily quantified in vivo and can be calculated from 
measurement of plasma and urine cAMP (UcAMP), after adjustment has been made for 
glomerular' filtration (47, 48). NcAMP almost exclusively reflects the effects of circulating 
PTH in normal individuals (45, 46, 49) and appears to be added directly to the tubular urine, 
thus accounting for the magnitude, rapidity and sensitivity of the PTH-induced changes in 
cAMP excretion. The determination of NcAMP, therefore, provides a sensitive and specific 
assessment of parathyroid function and a reliable index of the circulating activity of PTH on 
kidney and bone in both physiological and pathophysiological conditions (47, 50). 
Simultaneous measurement of PTH and NcAMP has recently been used to demonstrate the 
phenomenon of target organ insensitivity to PTH in patients with AGHD (51). Ca infusion 
studies have also demonstrated insensitivity at the level of the parathyroids themselves in 
these patients (52). It has previously also been suggested that renal sensitivity to the effects of 
PTH is decreased in untreated women with osteoporosis who demonstrate a less pronounced 
renal cAMP response to changes in PTH (53, 54). Also post-menopausal women with
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osteoporosis have shown less suppression of PTH (1-84) in response to PTH (1-34) infusion 
than normal postmenopausal women at various Ca concentrations, suggesting parathyroid 
gland insensitivity to changes in Ca concentration in this group of patients (55). It is possible, 
therefore that alterations in the end-organ responsiveness to the effects of PTH and changes 
in parathyroid gland sensitivity may contribute to the skeletal changes leading to the 
development of age related osteoporosis in a manner similar to that observed in AGHD.
1.3.1.2. Circadian Rhythm of PTH
True endogenous PTH circadian rhythmicity is well established in healthy individuals (56- 
58) and there is increasing evidence that fluctuations in PTH secretion may have an important 
effect on bone remodeling (59-66). The circadian rhythm of PTH is characterised by biphasic 
peaks of PTH concentration occurring in the early evening and at night (56-58). The 
nocturnal peak in PTH concentration is larger than the early evening peak and appeal's to 
have an important effect on bone remodeling (66, 67). Temporal fluctuations in PTH are 
necessary for its biological activity, a fact that is well demonstrated by primary 
hyperparathyroidism which is associated with a loss of PTH circadian rhythmicity (60), an 
increase in osteoclast cell number and activity (68) with the release of Ca, PO4 and matrix 
components of collagen from bone leading to the subsequent development of osteoporosis 
(59, 68).
The importance of fluctuation in PTH concentration, for biological effect, is further 
reinforced by studies in which intermittent and continuous PTH have been administered (62- 
65). Intermittent PTH administration by subcutaneous injection is associated with increased 
indices of bone formation including increased osteoblast number, osteocalcin, osteoid surface
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and cancellous bone volume, as well as increased indices of bone resorption such as 
increased osteoclast number and resorption surface (69) but with a net anabolic effect. 
Continuous PTH infusion is associated only with increased markers of bone resorption and 
favours bone resorption with a catabolic effect (64).
The factors that initiate and regulate the circadian rhythm of PTH are as yet not fully 
understood. The nocturnal rise in PTH has previously been related to the circadian rhythm, of 
prolactin and sleep cycles (57, 70) suggesting an element of neuroendocrine control, but 
acute shifts in sleep timing did not alter the timing of PTH nocturnal rise arguing against such 
a relationship (71). Although the majority of the PTH component has been shown to be truly 
endogenous, there is evidence that other factors, especially ones that cause acute shifts in Ca 
and PO4, may contribute in maintaining the PTH secretory pattern (58).
Circadian rhythms in the serum concentrations of ionised Ca, total Ca and PO4 themselves 
have also been demonstrated in healthy subjects (72-75). There are, however, inconsistencies 
in the reported patterns of ionised and total Ca circadian rhythms with the nadir* in total Ca 
reported between 2400 and 0400 h, while that of ionised Ca in the late afternoon and evening 
(74-79). In some studies no circadian rhythmicity has been observed for ionised and total Ca 
in women (66). In contrast, the PO4 pattern has been the most highly reproducible of the 
mineral rhythms (74-79).
The biological origin and significance of these temporal variations in mineral concentrations 
are not well defined and the relationship between the circadian rhythm of ionised Ca and 
PTH has been inconsistent (58, 66, 67, 75, 79, 80). There is a negative feedback system for 
the regulation of Ca in extra-cellular* fluid which involves PTH acting directly on the kidney
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and bone and indirectly on the intestine. Although correlation analysis has suggested that 
changes in serum Ca precede that of PTH, it is difficult to explain the nocturnal rise in PTH 
occurring when ionised Ca levels are already increasing (75). PTH circadian rhythm also 
persists in subjects infused with Ca to maintain a steady serum Ca level (72) making ionised 
Ca an unlikely candidate to regulate PTH.
Both, acute (81-83) and chronic oral PO4 (84) intake increases circulating serum PO4 and 
PTH. In such circumstances a transient decrease in ionised Ca may contribute to PTH release 
but PO4 has been shown to stimulate PTH secretion independent of the concentration of 
ionised Ca (85, 86). A strong correlation exists between circulating serum PO4 and PTH and 
it has been suggested that PO4 has a direct interaction with PTH (87) and may regulate PTH 
circadian secretion (72, 81, 88) independent of Ca and l,25(OH)2D (89, 90). Cross 
correlation analysis has shown that the maximal relationship between the circadian rhythms 
of PTH and P04 exists when PTH follows PO4 by one and a half hours (51).
Various pathological conditions are associated with abnormal PTH rhythm and treatment of 
the underlying pathology has restorative effects on the rhythm. The loss of PTH circadian 
rhythm observed in primary hyperparathyroidism returns following parathyroid surgery (59, 
60). AGHD patients have also been shown to have clear* differences in PTH circadian rhythm 
as compared to normal controls, possibly related to the rhythm of circulating PO4 (51). GH 
replacement therapy in these patients has been shown to have beneficial effects on restoring 
the circadian rhythm of PTH (91-94). PTH circadian rhythm is also altered in 
postmenopausal women both with and without osteoporosis and may have a role in the 
development of age-related osteoporosis (61, 66).
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1.3.2. Calcium and Phosphate Metabolism
The maintenance of serum Ca within normal limits is accomplished through the complex 
interplay of various hormones including PTH and vitamin D, acting on various organs via a 
number of different receptors (95-97). The calcium-sensing receptor on the parathyroid gland 
cells is highly sensitive to very small changes in Ca concentration, and feedback from 
circulating Ca completes the feedback loop (98). An inverse sigmoidal relationship exists 
between PTH secretion and extra-cellular Ca concentration (98) and the sigmoid curve is 
described by the maximal PTH secretory rate, the slope of the curve at the point where PTH 
secretion is at half its maximal rate, the Ca set point (the Ca concentration at which the rate of 
PTH secretion is half its maximal value) and the minimal PTH secretory rate (Figure 1.1.).
Figure 1.1. Schematic Representation of Calcium Set Point
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PTH, largely regulates ionised Ca levels directly through its actions on PTH receptors 
expressed abundantly on the kidney and bone, which are the primary target organs for PTH 
action (99-102), PTH-dependent regulation of mineral ion homeostasis also occurs indirectly 
through the stimulation of l,25(OH)2D and its action on the intestine (95-97).
In the kidney, PTH regulates Ca homeostasis by stimulating the reabsorption of Ca, inhibiting 
reabsorption of P04 and enhancing the synthesis of l,25(OH)2D. The majority of glomerular- 
filtered Ca is passively reabsorbed in the proximal tubule (103-105), but approximately 5% of 
Ca reabsorption is PTH dependent and occurs in the distal tubule by means of a combination 
of sodium-calcium channels and an ATP-driven Ca pump (104-106). Urine calcium (UCa) 
excretion reflects all the tubular reabsorption processes and the filtered load of Ca. PTH 
dependent renal reabsorption of Ca increases with increasing PTH concentration but the 
absolute amount of Ca excreted in the urine increases as the circulating Ca concentration 
increases. This increase in UCa excretion is especially seen when the circulating 
concentration of PTH is chronically increased and results in hypercalcaemia; such as in 
patients with primary hyperparathyroidism. This increase in UCa excretion is caused by the 
substantial increase in the filtered load of Ca (107, 108). The calcium-sensing receptor plays, 
independent of PTH, an important role in directly regulating renal Ca reabsorption by 
inhibiting tubular reabsorption of Ca when the level of peritubular Ca increases (98).
PTH also stimulates microsomal vitamin D 1 tx-hydroxylase in proximal tubular cells that 
leads to an increase in serum l,25(OH)2 D concentration (40, 109), which in turn, is a potent 
inducer of both intestinal Ca absorption as well as of bone resorption. This effect of PTH is 
not immediate, because the stimulation of l,25(OH)2D production occurs over several hours 
and requires the synthesis of new protein (110, 111) and therefore the consequent rise in Ca
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occurs more slowly than that achieved by the direct action of PTH on bone and renal Ca 
reabsorption. In addition to PTH, hypophosphataemia is a potent stimulator of la- 
hydroxylase activity whereas, Ca and l,25(OH)2D itself suppress la-hydroxylase as part of 
normal homeostasis (112, 113).
25-hydroxy vitamin D [25(OH)D] also undergoes hydroxylation to 24,25-dyhydroxy vitamin 
D [24,25(OH)2D] (114). Hydroxylation to 24,25(OH)2D reduces the availability of 25(OH)D 
for hydroxylation to l,25(OH)2D (115). PTH suppresses vitamin D 24-hydroxylase activity in 
the kidney, thus increasing substrate available for the production of l,25(OH)2D (112).
PTH effects on bone results in increased bone resorption within 1-2 h either as result of the 
direct effect of PTH activation of mature osteoclasts or via an initial activation of osteoblasts 
(116), which then through cellular and humoral paracrine mediators stimulate osteoclasts (96, 
97). Increased resorption results in breakdown of the calcium-phosphate matrix product and 
Ca release from bone stores into circulation. The homeostatic system has negative feedback 
elements, and restoration of serum Ca towards normal directly inhibits PTH synthesis while 
l,25(OH)2D provides an additional feedback loop (117-119). Hypercalcaemia acutely inhibits 
PTH release and more prolonged elevations result in suppression of PTH gene expression 
(120). Hypercalcaemia, generated by the sustained increases in PTH, suppresses the 1 a- 
hydroxylase activity and thus limits the production of l,25(OH)2D in a homeostatic manner 
(112, 113). It was initially thought that there was a linear relationship between serum Ca and 
PTH (121). Subsequently, several groups have shown a sigmoidal relationship between 
serum PTH and Ca (122-125).
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The Ca set-point (the Ca concentration at which the rate of PTH secretion is one half of its 
maximal value) (126) of the parathyroid gland plays a key role in “setting” the level of serum 
Ca (127) and not surprisingly, changes in the set-point of the pamthyroid gland produce 
major changes in PTH secretion at any given level of serum Ca (123) and in turn, the steady 
state level of the serum Ca concentration. Increase in the set-point are typically seen in 
hyperparathyroid (123) and in familial hypocalciuric hypercalcaemic states (128, 129), 
implying varying degrees of Ca resistance of the pai-athyroid/Ca sensing mechanism in these 
conditions. It is, therefore, possible that qualitative changes in Ca-regulated PTH release may 
play an important role in the secretory control of normal as well as abnormal parathyroid 
tissue.
The kidney plays the dominant role in systemic phosphorus homeostasis and PO4 enters the 
renal tubules after glomerular filtration and is reabsorbed in both the proximal and distal renal 
tubules. The rate of reabsorption is dependent upon the renal threshold for PO4 excretion, also 
known as the maximal tubular' phosphate reabsorption rate (TmPCVGFR; (GFR = glomerular' 
filtration rate)) and the serum phosphorous concentration is maintained by the kidney at a 
value very close to the TmPCVGFR (130). The systemic supply of phosphorus is very rarely 
a limiting factor and most disorders in humans relating to PO4 homeostasis result from either 
intrinsic or extrinsic alterations in TmPCVGFR. TmPCVGFR is affected by vardous factors 
including PTH, vitamin D and GH (131-136). PO4 reabsorption is inhibited by PTH (107, 
108) producing phosphaturia via inhibition of sodium-dependent PO4 transport (137). The 
PTH receptors in the proximal tubule that mediate the regulation of TmPCVGFR and those in 
the distal nephron that regulate Ca reabsorption are coupled to different intracellular' signal- 
transduction systems. The sequence of events in the face of a hypophosphataemic challenge 
includes stimulation of l,25(OH)2D synthesis in the kidney, enhanced mobilisation of
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phosphorus and Ca from bone and a hypophosphataemia-induced increase in TmPCVGFR, 
the exact mechanism of which is unknown. The increased circulating concentration of 
l,25(OH)2 D leads to increase in phosphorus and Ca absorption in the intestine and provides 
an additional stimulus for phosphorus and Ca mobilisation from bone. Thus there is an 
increase in flow of Ca from bone and intestine resulting in inhibition of PTH secretion. The 
inhibition of PTH diverts the systemic flow of Ca into the urine and further increases 
TmPCVGFR. The net result of this sequence of adjustments is a return of serum PO4 
concentration to normal without change in the serum Ca concentration (138).
More recently, distinct tubular PO4 transporters and a group of PO4 regulating peptides called 
phosphatonins that also regulate the TmPCVGFR have been identified and have increased the 
understanding of the mechanisms involved in renal PO4 handling (139-142). Fibroblast 
growth factor-23 (FGF-23) is a phosphatonin (30 Kda, 251 amino acids) (143, 144) that has 
been shown to have a physiological role in maintaining PO4 concentrations within a defined 
range as well as a role in pathological conditions (145-149). FGF-23 in turn is regulated by 
changes in PO4 (145, 150). FGF-23 decreases extracellular fluid PO4 concentrations by 
directly reducing renal PO4 reabsorption and suppressing 1,25 (OH)2D formation independent 
of PTH (146-149). In vitro, FGF-23 binds to known FGF receptors (FGFR) and it is assumed 
that FGF-23 mediates its effects in vivo through a known FGFR. FGF-23 regulates PO4 
metabolism by impairing PO4 reabsorption, at least in part, via a PTH independent decrease 
in the NaPi Ha (specific sodium/inorganic P04co-transpoiter) protein in the brush border 
membrane of renal proximal tubules (146, 148). It also has an NaPi Ha independent 
mechanism of action possibly mediated via the recently identified NaPi lie dependent renal 
reabsorption pathway (151, 152) or via the type III sodium PO4 cotransporter, pit-1, which 
regulates PO4 transport in bone (153). FGF-23 mRNA expression demonstrated in kidney
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also raises the possibility of an autocrine or paracrine role for FGF-23 in regulating renal 
transport (150).
1.3.3. The GH / IGF-1 Axis and Bone
GH and IGF-I are important regulators of bone homeostasis throughout life (154). Their 
effects on longitudinal bone growth, skeletal maturation and acquisition of peak adult bone 
mass are well established (155, 156). It is also proposed that GH and IGF-1 are important for 
the maintenance of bone architecture and mass in adulthood but their roles following 
complete maturation of the skeleton and attainment of peak bone mass is less clear (157, 
158). Changes in bone structure and increased bone mass in patients with GH excess and 
acromegaly are well documented, but it is not until relatively recently that advances in 
laboratory techniques have, together with the increased availability of recombinant human 
GH (rhGH), allowed further understanding of the role of GH in bone remodeling. GH 
stimulates bone turnover, beginning with an increase in bone resorption. The initial increase 
in bone resorption results in an increased number of bone multicellular units and the 
production of unmineralised bone, that leads to an apparent lower or unchanged bone mass 
on measurements of BMD. Bone resorption is then coupled to bone formation and as the 
effect of GH on osteoblasts is more pronounced and prolonged than on osteoclasts the rate of 
bone formation exceeds that of bone resorption resulting in an increase in bone mass (91).
The complex effects of GH on bone are direct as well as indirect and have been elucidated 
through studies in animals and different groups of human subjects including patients with 
AGHD and patients with age-related or postmenopausal osteoporosis.
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I.3.3.I. Direct Effects of GH
The effect of GH on bone appears to occur through a combination of direct and indirect 
actions. The direct effects of GH include stimulating the proliferation of cells of the 
osteoblast lineage (159, 160) and inhibiting osteoblast apoptosis (161). GH affects the fate of 
mesenchymal precursors directly, opposing adipogenesis and favoring osteoblastogenesis as 
well as chondrogenesis (162). It stimulates bone formation by expressing bone 
morphogenetic proteins, important for the differentiation of osteoblasts (163-165) and also 
stimulates the differentiated function of mature osteoblasts. GH also stimulates the 
carboxylation of osteocalcin as well as the synthesis of type 1 collagen and alkaline 
phosphatase (ALP) which ar e markers of osteoblastic function (166-168). GH exerts its direct 
effects on osteoblasts by binding to single-chain transmembrane glycoprotein receptors that 
belong to the cytokine/haemopoetic growth factor receptor family and have been identified 
on human and murine osteoblasts (169). The GH receptor consists of an extracellular', a 
transmembrane and an intracellular domain. Activation of the receptor occurs by ligand 
induced dimerization and internalization of the receptor to initiate signaling, primarily by the 
activation of the Janus tyrosine kinase 2 (JAK 2) in the cytoplasm (170). This leads to auto­
phosphorylation and to phosphorylation of the internalized GH receptor and recruitment and 
activation of intracellular' proteins of which the signal transducers and activators of 
transcription (STAT) are the most important (171-174). GH also signals through extracellular 
signal-regulated kinases (ERK) 1 and 2, mitogen activated protein kinases (MAPK) that 
regulate osteoblastic cell growth (175-178). Acting through STATs and ERKs, GH may 
modulate the activity of runt related transcription factor-2 (runx-2), which is an intracellular 
protein required for osteoblast cell differentiation (179, 180).
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Although a GH receptor is yet to be identified on osteoclasts (181), in vitro studies have 
shown that GH is able to directly stimulate the proliferation and differentiation of osteoclasts. 
GH is also thought to be directly involved in the coupling process of bone resorption and 
formation, perhaps through the release of IL-6 (157).
I.3.3.2. Indirect Effects of GH: IGF-1
The indirect action of GH occurs through stimulation of systemic IGF-1 production from the 
liver as well as IGF-1 expressed locally in bone. The physiology of IGF-1 is complex as it 
acts as a circulating hormone and as a local growth factor that can act in a paracrine as well 
as autocrine fashion in a variety of tissues including cartilage and bone. IGF-1 produced 
locally in the bone appears to be important for the development and function of osteoblasts 
and osteoclasts, probably at a point further along the line of differentiation than the steps 
requiring direct GH action (182, 183). IGF-I has modest effects on the proliferation of cells 
of the osteoblastic lineage, and although IGF-I does not direct the differentiation of 
undifferentiated stromal cells toward cells of the osteoblastic lineage, IGF-I enhances the 
function of the mature osteoblast (184, 185). Thus the fundamental role of IGF-I is the 
stimulation of osteoblastic function and bone formation. IGF-1 signals through the IGF-1 
receptor (IGF-1R), a transmembrane glycoprotein tetramer with ligand activated tyrosine 
kinase activity. Upon ligand binding, the IGF-1R dimerizes and undergoes 
autophosphorylation, leading to the activation of the insulin receptor substrate (IRS)-l and 
IRS-2 (186). IRS-1 and -2 mediate the effects of IGF-I in osteoblasts.
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IGF-1R expression has been demonstrated on human preosteoclasts (187). In vitro studies 
suggest that GH enhances osteoclast formation and activates mature osteoclasts indirectly via 
IGF-1 secreted by local stromal cells of osteoblast lineage (24, 25, 188, 189) thus acting as a 
coupling factor between bone resorption and formation (190). IGFs previously embedded in 
newly formed bone by osteoblasts are released when bone is resorbed, thus enabling the 
stimulation of further new bone formation.
I.3.3.3. Indirect Effects of GH: Phospho-calcium Metabolism
GH also influences bone metabolism indirectly by the modulation of phospho-calcium 
metabolism and by interaction with hormones including PTH and 1,25(OH)2D (191). The 
ability of GH to cause retention of Ca in man was first described by Beck et al. (192) and 
subsequently by Henneman et al. (193). It has been suggested that GH and IGF-1 may have a 
permissive role in the stimulation of vitamin D la-hydroxylase (135) whilst suppressing the 
24-hydroxylase (194) thus increasing the production of the active l,25(OH)2D, and 
consequently resulting in an increase in intestinal Ca and PO4 absorption. Sensitization of gut 
epithelium to l,25(OH)2D requires the presence of GH as well (195). This has been 
demonstrated by the reduction in levels of vitamin D dependent Ca binding protein in the 
intestine of hypophysectomised rats that increase following GH treatment (196, 197).
GH also increases serum PO4 concentration by potentiating renal PO4 reabsorption by 
increasing the renal tubular threshold for PO4 excretion also known as the TmPCVGFR (131, 
198). Children and adolescents have been shown to have a higher TmPCVGFR and serum 
PO4 concentrations than adults and this is likely to be an effect of the higher GH levels 
associated with growth and puberty (199, 200). The effect of GH on TmP04/GFR is mediated
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by locally produced renal IGF-1, and appears to be independent of PTH and vitamin D (131- 
136, 201). Thus, GH has an antiphosphaturic effect and supports PO4 retention. These 
mechanisms may contribute to an increase in extracellular calcium-phosphate product, and 
possibly bone mineralization.
I.3.3.4. Indirect Effects of GH: PTH
Studies have shown that GH and IGF-1 influence bone metabolism indirectly by affecting the 
end-organ effects of PTH, the anabolic actions of PTH on bone (91, 93, 94, 202-204) and by 
modulating PTH secretion and its circadian levels (91, 93, 94, 205). This effect is mediated 
in part by changes in serum PO4 levels (51, 58) as the serum PTH peaks around 0500 h 
coinciding with the serum PO4 peak (89, 206, 207).
1.4. Biochemical Markers of Bone Turnover
Osteoid matrix consists principally of collagen, of which the main structural protein is type 1 
collagen. All collagens contain molecular domains of triple helical conformation which 
require the presence of repeating amino acid sequences. Proline and hydroxyproline feature 
prominently within the sequences. The collagen propeptide has amino (N) and carboxyl (C) 
terminal extensions which are cleaved by specific peptidases and released into the circulation, 
prior to the cross-linking of collagen molecules (208). The type 1 procollagen peptides, 
procollagen type 1 carboxyterminal propeptide (PICP) and procollagen type 1 aminoterminal 
propeptide (PINP) can be measured in serum as markers of bone formation. Other markers of
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bone formation which are released into the circulation as a by-product of osteoblast activity 
include alkaline phosphatase and osteocalcin.
Bone resorption occurs as a result of osteoclast secretion of acid and neutral proteases which 
act sequentially to degrade the collagen fibrils into molecular fragments. The circulating 
products range in size from free amino acids to segments of cross-linked N-telopeptide and 
C-telopeptide domains. The fragments are metabolised by the liver and kidney until all 
fragments are sufficiently small to be excreted in the urine. The products of bone resorption 
which include hydroxyproline, C-telopeptide (CTX) and N-telopeptide (NTX) can be 
measured in serum or urine and used as markers of bone resorption. Acid phosphatase is a 
product of osteoclasts which may also be used for the assessment of bone resorption.
1.4.1. Assessment of Bone Turnover
Ideally, methods used to assess bone turnover should be minimally invasive and reproducible, 
allowing for easy and frequent measurement over time without undue risk or discomfort to 
the patient. Bone remodeling can be assessed most accurately using radiolabelled Ca kinetic 
studies, however the technique is expensive and time-consuming, and therefore generally 
limited to use as a research tool (209). Dynamic histomorphometry of bone biopsy samples 
may also be used to assess bone status, but obtaining bone samples is invasive and the results 
from a single core biopsy may not apply to all skeleton sites (209). Any technique used to 
assess bone remodeling should correlate with standard methods of assessing bone 
remodeling. In addition, for validation, the technique should correlate to changes in bone 
mass and respond appropriately after treatment in pathologies known to affect bone 
resorption or formation.
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Recent advances in the development of sensitive assays for urine and serum markers of bone 
turnover has greatly increased the ability to assess bone remodeling in both research and 
clinical settings (209-211). The measured markers of bone turnover are either the products of 
bone collagen synthesis or catabolism, or the products of osteoblast or osteoclast cell activity; 
thus concentrations reflect collective remodeling throughout the entire skeleton and not just 
activity at a specific site.
The earliest markers of bone turnover to be used were ALP and urine hydroxyproline (211- 
215). Although both correlate well with Ca kinetic studies, they both lack specificity (215). 
Hydroxyproline is present in collagen which is ubiquitous to all tissues of the body and 
therefore changes in excretion of hydroxyproline do not necessarily equate to differences in 
bone resorption (209). ALP is secreted by several other tissues, predominantly liver, kidney 
and spleen and therefore measurements of total ALP may not accurately represent changes in 
bone formation. Assays for bone-specific ALP do exist and correlate well with Ca kinetic 
studies in Paget’s disease and osteomalacia but less well in primary osteoporosis (216).
The newer markers of bone turnover, N- and C-propeptides and cross-linked N- and C- 
telopeptides of type 1 collagen, have the advantage that they are specific to bone metabolism. 
PINP and PICP are amongst the most sensitive markers available of bone formation and have 
been extensively used and validated in the assessment of bone formation in health and disease 
(216-222). Comparative studies have shown that PINP is more sensitive and reliable in 
predicting bone formation compared to PICP (216, 217, 221, 222).
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CTX and NTX have been shown to be more sensitive to changes in bone resorption occurring 
at the menopause and during treatment with antiresorptive agents, than other available 
markers of bone turnover (211, 223-225). The measurement of urine cross-linked 
telopeptides, however, does have a number of disadvantages including collection of timed 
samples and the need to correct for renal function (226). More recently, the development of 
assays to measure serum type-I collagen (3 C-telopeptide (PCTX) has further improved the 
assessment of bone resorption (211, 223-225). Serum (3CTX has been shown to be a specific 
and sensitive index of bone resorption, in both healthy controls and states of bone pathology 
(211, 223-225).
Markers of bone formation and resorption are secreted in circadian rhythms, with peaks 
occurring during the night and nadir's at approximately 10 am (67, 227, 228). It has been 
postulated that the circadian rhythm of bone turnover markers probably has an endogenous 
component and can also be affected by exogenous factors such as endocrine hormones 
including cortisol, PTH and calcitonin that have circadian rhythms and can modulate bone 
turnover. PTH has been shown to be important in the regulation of the circadian rhythm of 
bone turnover, with changes in PTH preceding those in osteocalcin by 5 hours (229-231). The 
physiological implications of the circadian rhythmicity of bone turnover are unclear-, but there 
are suggestions that it may be important in the regulation of Ca homeostasis (67). In patients 
with postmenopausal osteoporosis, a blunted nocturnal PTH concentration is associated with 
increased renal Ca loss and exaggerated nocturnal peak in markers of bone resorption. The 
increased nocturnal bone resorption occurring in osteoporosis may be a compensatory 
mechanism to maintain serum Ca concentration (67), as evidenced by the suppression of a 
nocturnal rise in bone resorption following evening supplementation with Ca (232).
52
1.5. GH, IGF-1 and the Development of Osteoporosis - The 
AGHD Model
1.5.1. The GH/IGF-1 Axis and AGHD related Osteoporosis
AGHD in addition to its other characteristic features is associated with an increased risk of 
osteoporosis and osteoporotic fractures (231, 233-238) thus providing a model to study the 
effects of the GH/IGF-1 axis on bone. Initial studies performed in adults with childhood- 
onset GHD concluded that the reduction in BMD detected in adulthood occurred as a result 
of failure to attain peak bone mass during development (239-241). However, subsequent 
reports have confirmed an increased prevalence of osteoporosis in AGHD compared with a 
matched, healthy population where the study populations have been made up exclusively of 
adult-onset GHD patients (231, 233-238). Decreased BMD was also specifically observed in 
patients who were estimated to have developed AGHD after the age of 30 years, and 
therefore, after the attainment of peak bone mass (234-238) providing further evidence that 
GH is required not only for the acquisition but also the maintenance of bone mineral mass. 
Furthermore, the severity of AGHD, as defined by stimulated peak GH, has been correlated 
with bone loss, and FN and lumbar spine (LS) T-scores are significantly lower in those with 
severest impairment of GH secretion (242).
The pituitary aetiology and therefore high prevalence of abnormalities in sex steroid 
deficiency in patients with AGHD had led to the suggestion that it may have been oestrogen 
deficiency rather than GH deficiency that was responsible for the abnormalities observed in 
BMD (157). However, reduced BMD has been demonstrated in AGHD patients who have
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normal gonadal function (233) and no difference in BMD was observed when patients who 
had isolated GHD were compared with patients who had co-existent gonadotrophin 
deficiency (235). There have however been gender based differences in the responses of 
patients with AGED to GH replacement therapy and women have been found to be less 
responsive to the effects of GH (93).
Most studies have shown that bone formation is reduced in AGED (51, 243-245). Bone 
resorption appeal's not to be significantly different (246-248) or reduced (51) in AGED 
patients compared with healthy controls. The negative equilibrium between formation and 
resorption, and reduced bone remodeling are therefore likely to underlie the development of 
osteoporosis in AGED.
1.5.2. AGHD and Bone Metabolic Parameters
I.5.2.I. AGHD and PTH
Studies that have looked at PTH changes in AGHD have been associated with increased, 
decreased or unchanged concentrations of PTH (249-251). The reason for such conflicting 
reports is likely to be an effect of the single time point measurements performed in the 
methodology of these studies (51). PTH is secreted in a circadian rhythm (56-58, 252) and, as 
a result shows significant day-night variability. Therefore, the timing of venesection for PTH 
analysis is critical to avoid misleading results, Ahmad et al recently demonstrated that a 
variability in sampling timing of as little as 2 hours may result in significant differences in 
PTH concentration (51). The only study to date to determine the effect of AGHD on PTH 
concentration whilst excluding the confounding sampling time variable was also performed
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by Ahmad et al. (51). The authors took blood samples every 30 minutes from 14 AGHD 
patients and 14 matched healthy controls for a 24 hour period. They conclusively found that 
the mean 24-hour PTH concentration and the PTH concentration at each individual time point 
was significantly higher in the AGHD patients compared with the healthy controls, therefore 
suggesting that AGHD is associated with a relatively increased PTH concentration.
The determination of NcAMP has been shown to provide a sensitive and specific assessment 
of parathyroid function and is a reliable index of the circulating activity of PTH on the kidney 
and bone in both physiological and pathophysiological states (47, 50). Early reports 
suggested a reduction in NcAMP in patients with AGHD (253), which has been confirmed 
more recently in a cross-sectional study comparing AGHD patients with healthy controls 
(51). In this latter study, the reduced NcAMP occurred in association with an increase in 
mean 24-hour PTH concentration and reduction in serum adjusted calcium (ACa) and 
markers of bone turnover, suggesting that AGHD is associated with a reduction in the 
sensitivity of the target organs to the effect of PTH. The authors concluded that reduced PTH 
target-organ sensitivity may underlie the pathogenesis of reduced bone turnover and 
development of osteoporosis in AGHD.
Infusion of PTH into AGHD patients is associated with a delayed and reduced calcaemic 
response (52) and supports the hypothesis of reduced sensitivity of target organs to the effects 
of PTH. AGHD is also associated with a reduction in the responsiveness of the calcium­
sensing receptor to both hypo- and hypercalcaemic stimuli with a reduction in the Ca set 
point (52). Both factors are thought to be important in the development of abnormalities in Ca 
metabolism seen in AGHD, and thereby in the contribution to a reduction in bone mass.
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Circadian variability and temporal fluctuations in PTH are necessary for its biological activity 
(59-66). Abnormalities in the circadian, biphasic rhythm of PTH contribute to bone loss in 
various conditions (59, 66, 67). Patients with AGHD have been shown to exhibit significant 
PTH circadian rhythmicity but with a blunted nocturnal rise and a sustained early evening 
rise in PTH concentration (51); changes which may contribute to the pathogenesis of 
osteoporosis in AGHD.
1.5.2.2. AGHD and Calcium Metabolism
Limited published data exists, however, on the effect of GH deficiency on circulating Ca, An 
earlier study, investigating young adults with childhood-onset GHD, found no difference in 
serum Ca compared with healthy controls (241). No difference in PO4 concentrations, PTH 
concentrations, intestinal Ca absorption or Ca and PO4 excretion were found either. However, 
all patients studied had previously received GH prior to the study and single time point 
measurements were used. These findings may thus have been inaccurate and a more recent 
study did show that serum ACa concentration was significantly lower in AGHD patients 
compared with controls (51). In this study, blood was taken every 30 minutes for a 24 hour 
period in truly GH naive patients and healthy controls. The 24-hour mean serum ACa 
concentration was calculated and compared between the groups and therefore gives a more 
accurate reflection of serum Ca concentration than the earlier study. The reduction in serum 
ACa seen in AGHD patients was explained by a reduction in renal sensitivity to PTH and so 
resultant decreased renal Ca reabsorption, together with a reduction in PTH mediated la- 
hydroxylase activity.
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1.5.2.3. AGHD and Phosphate Metabolism
GHD is associated with a relative phosphate deficiency which occurs through a combination 
of reduction in GH-mediated TmPOVGFR resulting in phosphaturia and reduced intestinal 
PO4 absorption (51, 191, 254). The absorption of PO4 from the small intestine is decreased as 
a consequence of GH-dependent desensitisation of the intestine to l,25(OH)2D and reduction 
in l,25(OH)2D concentration occurring as a result of decreased PTH-mediated renal vitamin 
D la-hydroxylase activity (51, 157, 195). Although the reduced PTH target-organ sensitivity 
associated with AGHD would result in some renal PO4 retention, the direct effect of the 
GH/IGF1 axis on TmPCVGFR and vitamin D metabolism appear to be greater and result in a 
net PO4 loss (51).
1.5.3. AGHD and Growth Hormone Replacement
I.5.3.I. Bone Mineral Density
Growth Hormone Replacement (GHR) in AGHD has been associated with a reduction in 
BMD during the initial 3 months of treatment (255-257). This initial decrease may be 
explained by the increased remodeling activity occurring with GHR, that results in increased 
remodeling space and an increase in new unmineralised bone. BMD then increases as early as 
6 months (243, 246, 255, 256, 258-263), and thereafter, bone mass continues to increase as 
long as GH is replaced and has been reported to continue increasing even as long as 10 years 
(264, 265). Discontinuation of GHR is not associated with immediate bone loss and BMD 
may actually continue to increase for at least 12 months after discontinuation of GH, 
suggesting a prolonged effect of GH on bone metabolism (266). Response to GHR appeal's to
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depend on factors such as age, gender and body mass index (93, 94, 267, 268), At present 
there are not any studies which have investigated the effect of GHR on reduction in risk of 
fractures. BMD has been shown to correlate with risk of osteoporotic fracture, which may 
suggest that GHR could reduce fracture risk in the long term.
I.5.3.2. Bone Turnover
Data from several placebo-controlled studies have reported that GHR is consistently 
associated with a significant increase in all markers of bone resorption and bone formation 
(248, 269, 270). An increase in bone turnover has been confinned by histomorphometric 
assessment (271). Increases in bone resorption and formation appear- to occur as early as 1 
and 3 months, respectively, following the initiation of GHR (91). The increase in markers of 
bone resorption, followed closely, temporally, by an increase in markers of bone formation 
supports the concept of coupling of bone turnover where resorption precedes formation, 
ultimately resulting in increased bone mass (91). Increases in markers of bone turnover may 
be sustained for at least 2 years after the initiation of GHR, suggesting that the effect of GH 
on bone remodeling is persistent, a concept supported by the progressive increase in BMD 
with discontinuation of GHR (258, 264, 267, 268, 272). Even after short term treatment with 
GH, markers of bone turnover remain elevated for several weeks indicating that GH has a 
prolonged effect on bone remodeling, in keeping with the sustained increase in bone mass 
observed following discontinuation of GHR (266). The mechanism of this “catch-up” is not 
readily apparent, although there are some interesting possibilities. First, it has long been 
recognized that GH, IGF-I, and PTH all stimulate bone resorption while activating bone 
formation. IGF-I stimulates RANKL expression in a dose dependent manner and down 
regulates OPG in ST-2 cells. These findings suggest that bone turnover with anabolic agents
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is accelerated by targeting stromal cells, which in turn generate not only growth factors that 
increase bone formation, but also cytokines that are necessary for osteoclast recruitment and 
differentiation. Thus, discontinuation of rhGH might lead to an immediate cessation in IGF- 
I-mediated RANKL expression, while at the same time continuing the stimulatory actions on 
osteoblasts initiated earlier during treatment.
1.5.33. PTH
The results of earlier reports investigating the effect of GHR on PTH had been conflicting 
with increased, decreased or no change in concentration detected (91, 196, 249, 250, 253). 
The different outcomes observed may have been due to single time point sampling not 
accounting for the circadian variability of circulating PTH (51). In a more recent study, PTH 
was measured on blood samples that were taken every 30 minutes over a 24 hour period thus 
eliminating any error associated with single-time point sampling methodology (91). PTH 
decreased significantly following 1 month of GHR, with maximal changes occurring after 6 
months. In the same study, NcAMP increased significantly after 1 month of treatment, 
suggesting that GH resulted in an increase in renal sensitivity to the effects of PTH. PTH (1- 
34) infusion is associated with larger and earlier increases in serum ACa concentration in 
AGHD patients after GHR than prior to GHR which supports the concept of an increase in 
PTH target-organ sensitivity (52). An increase in parathyroid gland sensitivity to smaller 
changes in serum Ca concentration was also observed following GHR, with a lowering of the 
Ca set point (52). With the 24 hour sampling the effects of GHR on PTH circadian rhythm 
were also studied and GHR was associated with an increase in the nocturnal PTH peak and a 
restorative effect on the PTH circadian rhythm (91).
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I.5.3.4. Calcium
The majority of studies investigating the effect of GHR in AGHD have shown that GHR is 
associated with an increase in serum Ca concentration (52, 91, 249, 262, 273). This may 
occur as a result of increased renal sensitivity to PTH, as evidenced by a simultaneous 
reduction in PTH concentration and increase in NcAMP (91), thus leading to increased renal 
tubular- Ca reabsorption. Increased renal PTH sensitivity following GHR would also increase 
PTH mediated la-hydroxylase activity and thus l,25(OH)2D concentration, thereby 
increasing serum Ca concentration further. Finally, GH sensitizes the small intestine to 
l,25(OH)2D potentiating the increase in intestinal Ca absorption (195).
I.5.3.5. Phosphate
GHR in AGHD is associated with an increase in serum PO4 concentration (91, 249, 262, 
273). The interplay of several mechanisms contributes to the increase of PO4 following GHR. 
The dominant effect of GHR on PO4 is an increase in TmPCVGFR (198, 254) which 
promotes an antiphosphaturic effect, and a reduction in 24-hour urine PO4 excretion (91). The 
effect of GHR on TmPCVGFR appears to be the result of a direct GH effect mediated 
through locally produced IGF-1 and occurring independently of PTH , UcAMP or 
l,25(OH)2D (131-135). The increase in l,25(OH)2D and GH-induced increased gut 
sensitization to l,25(OH)2D observed following GHR contributes also to the increase in 
serum PO4 through an augmentation of intestinal PO4 absorption (91, 195). In addition, it was 
previously proposed that the increase in serum Ca concentration that occured in response to 
GHR resulted in suppression of PTH, thereby decreasing PTH-mediated phosphaturia. In 
contrast, the more recent demonstration of increased renal PTH activity, as defined by an
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increase in NcAMP observed following GHR, would promote renal PO4 excretion (91). 
Therefore, the positive PO4 balance occurring following GHR is likely to represent the net 
positive effect of a greater, direct GH-mediated increase in TmP04/GFR, increased intestinal 
PO4 absorption and a PTH-mediated phosphaturia of lesser magnitude.
1.6. GH, IGF-1 and the Development of Age-related Osteoporosis
1.6.1. Age-related Changes in the GH/IGF-1 Axis
The complex role of the GH axis in bone metabolism is illustrated by the direct and indirect 
mechanisms of GH studied in various groups of subjects including patients with AGHD as 
described above. Our understanding of the role of GH on bone must also take into 
consideration the age-dependent decline in GH secretion during an individuaPs lifetime. This 
decline has been ascribed to changes occurring at the hypothalamic level, without a known 
cause, resulting in a decrease in GH releasing hormone, decreased central cholinergic tone 
and an increase in somatostatin secretion (274, 275). The decline in the production of sex 
steroids, physical activity, and the presence of aberrant sleep patterns also may contribute to 
the decline in GH levels during aging (276).
Serum levels of GH and IGF-1 decrease with advancing age reaching a nadir at the sixth 
decade (274, 277, 278). Variable reductions (15-70%) in 24-hour GH secretion have been 
demonstrated with the GH production rate decreasing by 14% with each advancing decade 
after puberty (277, 279-283). GH production decreases twice as rapidly in men than in 
women so that GH release remains higher in women than in men after the age of 50 (281,
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284). The changes in GH and IGF-I secretion that occur with aging are paralleled by a 
progressive loss of lean muscle mass and strength, a decline in physical performance, a 
decrease in quality of life, an increase in body fat and a decrease in BMD (BMD) (285-289), 
clinical features also seen in the syndrome of AGHD (290). It has been hypothesized, 
therefore, that the ageing process and particularly age related osteoporosis, previously 
referred to in the literature as type 2 osteoporosis, may be due to a relative GH deficient state 
(12, 290-292). A relative GH deficiency has also been implicated in the development of 
postmenopausal osteoporosis, previously referred to in the literature as type 1 osteoporosis 
(290), as oestrogen is required for the secretion of GH (293). Thus GH and IGF-1 may have 
a role to play in the continuous slow phase bone loss with advancing age and a possible 
additional role in the superimposed rapid phase bone loss immediately after the menopause.
1.6.2. Age-related Osteoporosis
Although pituitary GH content is normal in patients with type 1 and type 2 osteoporosis, the 
total 24-hour, peak and stimulated GH secretion are reduced compared with age-matched 
controls (294) thus supporting the concept of GH involvement in the pathogenesis of primary 
osteoporosis. IGF-1 and integrated GH secretion demonstrate strong correlation with BMD 
and have been reported to be significantly lower in women as well as men with osteoporosis 
(295, 296) and IGF-1 is an independent predictor of bone mineral content (BMC) even in 
healthy elderly women (297-299). Decreased IGF -1 concentration is associated with an 
increased risk of fractures (296) and patients with a recent hip fracture have decreased 
concentrations of GH and IGF-1 (300). In addition to lower IGF-1 concentration, post 
menopausal women with osteoporosis also have lower serum levels of insulin like growth 
factor 2 (IGF-2) and insulin like growth factor binding protein 3 (IGFBP-3) (301). Low
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circulating IGF-1 and IGFBP-3 ai’e associated with low rates of bone turnover as well as 
reduced BMD in the spine of men with idiopathic osteoporosis (299, 302, 303). IGF-1, IGF- 
2, IGFBP-3 and insulin like growth factor binding protein 5 (IGFBP-5) concentrations within 
femoral cortical and trabecular' bone microenvironment are also lower and decrease with 
advancing age in men with osteoporosis (278, 296, 304).
Thus GH and IGF-1 are involved in bone metabolism and the maintenance of bone mass in 
adults through the complex interaction of systemic circulating GH, IGFs, IGFBPs, locally 
produced IGFs and IGFBPs (154, 157, 158, 305, 306); the age related decline in GH and 
IGF-1 may contribute to the pathogenesis of age related osteoporosis (307-309).
1.6.3. Changes in Bone Metabolism with Age
I.6.3.I. Aging and PTH
PTH concentration increases with age (310-312) and is also higher in women with primary 
osteoporosis (311, 313-315). The increase has variously been attributed to decreases in renal 
function, residual oestrogen levels, Ca absorption, levels of and response to 25(OH)D as well 
as to aging itself (316-323). It has been a popular concept that the alterations in PTH may be 
causally related to bone loss in primary osteoporosis (313) and that the age related increase in 
PTH may contribute to the age related increase in bone resorption (324-326) .
The rapid bone loss phase in the immediate postmenopausal period is associated with a high 
rate of bone resorption. It is proposed that the increased resorption increases skeletal Ca 
outflow into the extracellular* pool, leading to a partial suppression of PTH secretion, a
63
compensatory increase in UCa excretion (16) and decreased intestinal Ca absorption (327) 
preventing hypercalcemia. It has also been observed that bone responsiveness to infused 
PTH is enhanced during the immediate postmenopausal rapid phase of bone loss (328) but 
this has been attributed to the overall increase in bone remodeling units seen in this phase 
(329).
As the rapid bone loss phase subsides, serum levels of PTH increase progressively throughout 
the remainder of life with an absolute increase in bone resorption and a relative decrease in 
bone formation involving equal losses of cortical and cancellous bone (330). The increases in 
PTH correlate with the increases of the biochemical markers of bone turnover (16). 24 hour 
infusion of Ca to postmenopausal women with elevated PTH and bone turnover markers was 
shown to decrease both PTH and bone markers suggesting that the increased PTH may be the 
cause of the increased bone turnover (324). Men do not have an equivalent of the rapid phase 
of bone loss that women experience following the menopause and after accounting for the 
absence of this phase, the patterns of late bone loss and of the increases in serum PTH and 
bone resorption markers in ageing men are virtually super-imposable upon those occurring in 
women (16).
The increase in PTH during the slow phase is also not associated with an increase in ionised 
Ca. This was considered indicative of secondary hyperparathyroidism as a result of age- 
related abnormalities in extra-skeletal Ca homeostasis. Studies demonstrating impaired 
intestinal Ca absorption and impaired renal Ca reabsorption with advancing age resulting in 
Ca loss would support this supposition (323, 324, 331-334). Decreasing serum concentrations 
of the vitamin D metabolites, 25(OH)D (335-337), l,25(OH)2D (320, 332, 336, 338-343) 
and the renal enzyme 25(OH)D la-hydroxylase (343) have also been demonstrated with 
ageing, and may contribute to the increasing PTH.
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The nocturnal rise in PTH secretion is absent in women with primary osteoporosis and there 
is blunting of the rhythm in postmenopausal women compared with premenopausal women 
even without a demonstrated decrease in BMD (66). Abnormalities in circadian rhythms of 
bone resorption and renal Ca conservation in postmenopausal osteoporosis have been shown 
to be associated with the blunting of the nocturnal rise in PTH secretion (67). Thus, changes 
in the circadian rhythm of PTH may have a role to play in the development of age related 
osteoporosis, but the factors influencing PTH rhythm as well as mechanisms by which the 
abnormal PTH rhythm may affect bone are unclear.
I.6.3.2. Aging and Calcium Metabolism
Serum total Ca has been reported to decrease progressively from the age of 20 upto the age of 
80 in men, but in women, some studies have reported no change in Ca concentration with age 
whilst some have suggested a minimal increase in serum Ca after the menopause. Aging and 
the menopause are however associated with a negative shift in Ca balance (344, 345). Thus, 
a number of different age-related observations have been reported on the complicated and 
multi-factorial regulation of Ca metabolism with various hypotheses proposed to explain 
these observations.
Aging is associated with changes in vitamin D metabolism which would impact on Ca 
homeostasis. It is reported that 25(OH)D, which is an indicator of vitamin D nutrition status, 
decreases by 30-60% in both genders with advancing age, probably as a result of poor 
nutrition, decreased intestinal absorption and inadequate exposure to sunlight. l,25(OH)2D
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has been reported to decrease by about 50% with aging and levels are lower in patients with 
osteoporosis as compared to age matched controls (336). The serum levels of calcitriol, 
however, overlap to a significant degree in young adults, in the elderly or elderly adults with 
osteoporosis and not all investigators have demonstrated these age related differences. The 
decrease in activated vitamin D is probably due to decreased renal production. The normal 
increase in l,25(OH)2D in response to infusions of PTH are blunted in the elderly as 
compared to young adults (343) and a primary impairment in the renal enzyme 24(OH)D la- 
hydroxylase, responsible for the conversion of 25(OH)D to l,25(OH)2D has been 
demonstrated directiy in kidney slices of aging rats. Aging may result in primary deficiency 
of 24(OH)D la-hydroxylase or a decrease in the renal sensitivity to PTH. Low 1 a- 
hydroxylase activity may be due, indirectly, to the absence of the permissive action of 
GH/IGF-I axis on the enzyme, as the GH/IGF-I axis may mediate the hypophosphataemic 
stimulus on renal 1 a-hydroxylase (135, 346, 347).
It is well established that intestinal Ca absorption efficiency declines with age as well as 
following the menopause and is lower in elderly people with osteoporotic fractures than in 
subjects of the same age without osteoporosis (336, 348-351). The decrease in intestinal 
absorption contributes to the negative shift in Ca balance (333, 336, 352-354) and is only 
partly attributed to the decrease in serum levels of calcitriol. Some reports however suggest 
that the decrease in Ca absorption begins about age 50 to 60 year’s, preceding the decrease in 
l,25(OH)2D and may even be due partly to decreased sensitivity of the intestine to the action 
of l,25(OH)2D (332) but this has not been observed in all studies (355). The decrease in 
oestrogen following the menopause (356, 357) as well as an age related decrease in the active 
intestinal transport mechanism (356) also possibly contribute to the decrease in Ca 
absorption.
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The negative Ca balance is also partly explained by increased UCa excretion which is greater 
in postmenopausal women than in premenopausal women and has been shown to be even 
greater in postmenopausal women with osteoporosis when compared with postmenopausal 
women with a normal BMD (358). Explanations proposed to account for the decrease in 
renal tubular Ca transport have included a direct effect of lower oestrogen on renal Ca 
absorption as well as an indirect effect of oestrogen via increased bone resorption leading to 
Ca release, ensuing PTH suppression and a resultant decrease in PTH effect on renal Ca 
reabsorption. The indirect effect is thought to be the predominant mechanism in the early 
postmenopausal period and the direct effect in later stages.
The increase in UCa excretion in women with osteoporosis has been shown to be maximum 
at night time and it has been suggested that this increased nocturnal loss may contribute to the 
blunting of the nocturnal PTH rhythm as well as to an increased in nocturnal bone resorption 
for maintenance of circulating ionised Ca concentrations overnight (67, 358). It has also been 
suggested that the decrease in Ca reabsorption may also be a result of decreased renal 
sensitivity to the action of normal serum levels of PTH (51, 359).
1.6.3.2.1.The Sequence of Metabolic Events
Various hypotheses have been proposed to account for the sequence of the complex 
metabolic events involving PTH, vitamin D and Ca that lead to bone loss.
(i) Decreased renal production of calcitriol, brought on by age-related decreases in renal 
function, deficiencies of gonadal steroids, or other factors, may be primary. Malabsorption of
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Ca follows and the reduced flow of Ca into the blood stimulates a reactive increase in PTH
secretion, which in turn increases renal secretion of calcitriol. While this response may 
maintain serum levels of calcitriol, the elevated levels of PTH produce bone resorption and 
eventual osteoporosis. Under this hypothesis, age-related bone loss occurs as a form of mild 
calcitriol deficiency with mild compensatory parathyroid-mediated bone loss.
(ii) Under another hypothesis the primary abnormality may be an imbalance between bone 
resorption and bone formation, brought on either by reduced physical activity, age, 
deficiency, or other factors. Because Ca released from the skeleton exceeds Ca taken up by 
the skeleton, PTH secretion is suppressed, with consequent reduction of calcitriol synthesis. 
Reduced efficiency of intestinal Ca absorption would thus constitute an appropriate 
adaptation to net flux of Ca from bone, exactly analogous to the adaptations which take place 
in response to the resorptive excess of bed rest.
Both hypotheses have, in common, decreased efficiency of intestinal Ca absorption, 
decreased levels of calcitriol in the serum, net bone resorption, and osteoporosis. However, 
the causal sequences are directly opposite, and the PTH levels differ under the two 
hypotheses. In discussing the complicated and often discrepant evidence for and against these 
hypotheses, it is important to bear in mind that both may be correct, but in different 
individuals and at different stages of bone loss with different patterns of bone loss. The 
former sequence of events would be in keeping with changes in the late slow bone loss phase 
whilst the latter hypothesis would be in keeping with the rapid bone loss phase in the 
immediate postmenopausal period.
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The development of osteoporosis in AGHD is also associated with the same spectrum of 
abnormalities in Ca, vitamin D and bone turnover. PTH concentrations are however higher in 
patients with AGHD than in healthy controls. Thus the overall biochemical picture is in 
keeping with the events in hypothesis (i) and age-related slow bone loss. The findings of 
Ahmad et al. however suggest that the primary biochemical abnormality in AGHD is PTH 
resistance as a result of low GH and IGF-1 concentrations. This results in the increased PTH 
concentration and simultaneous abnormality in Ca and vitamin D metabolism (51). This 
provides a third hypothesis: the age related decline in GH and IGF-1 may contribute to age 
related bone loss as result of PTH resistance as the first step in the sequence of metabolic 
events.
I.6.3.3. Aging and Phosphate Metabolism
Serum PO4 levels have been shown to decrease gradually with age in adult men in an almost 
lineai' pattern (360-363). The decline in serum PO4 levels in women under the age of 45 years 
is similar to that in men. Serum PO4 then increases between the ages of 45 and 54 year's or 
until after the menopause. Following this, levels progressively decline (360). Some studies 
have demonstrated a negative relationship between increased PO4 and decreased vitamin D 
(364, 365).
A greater phosphaturic effect as a result of higher PTH concentrations (107, 108) with 
increasing age may account for the decreasing PO4. One would also expect an increase in 
l,25(OH)2D as a result of the higher PTH. Increased vitamin D should in turn increase 
circulating PO4. This is however not the case as l,25(OH)2D concentrations decrease with 
age (336). Thus current hypotheses do not provide a unifying mechanism of events for PO4 
changes. PO4 metabolism is affected by the GH and IGF-1 axis. GH and IGF-1 independently
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increase TmPCVGFR. Theoretically, the age related decline in GH and IGF-1 may also 
affect PO4 metabolism by decreasing TmPCVGFR and increasing phosphaturia.
In patients with AGHD, PTH concentrations are increased in association with low GH and 
IGF-1 and l,25(OH)2D. Circulating PO4 concentrations are low and urine PO4 excretion is 
high with a low TmPCVGFR (51), The increase in circulating PTH is attributed to PTH 
resistance as a result of the low GH and IGF-1. Renal resistance to the effect of PTH also 
accounts for the low l,25(OH)2D. The low l,25(OH)2D in combination with the low 
TmPCVGFR (as a direct result of low GH and IGF-1) would account for the phosphaturia 
and lower circulating PO4. Thus, a unifying hypothesis applicable to age related changes in 
PO4 metabolism may be derived from the mechanisms elucidated in patients with AGHD.
I.6.3.4. Aging and Markers of Bone Turnover
Biochemical markers of bone turnover have been studied in several groups of women. Levels 
of both bone formation and resorption have been shown in some studies to increase during 
the perimenopausal and postmenopausal period but with a relatively greater increase in bone 
resorption markers as compared to formation (215). Some studies have shown an increase in 
resorption markers with no change in formation markers (366). In postmenopausal women 
with osteoporosis the markers of bone resorption are significantly higher when compared to 
women with out demonstrated bone loss, but with a relatively smaller increase in bone 
formation markers (215).
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Biochemical markers of bone turnover are less well studied in men than in women. Levels of
both markers of formation and resorption are high in young men and decrease with advancing 
age (367-370). In elderly men, bone resorption increases with age more than bone formation. 
In elderly men, levels correlate negatively with BMD suggesting that accelerated bone 
turnover or the imbalance of a greater increase in bone resorption compared to bone 
formation may underlie age-related bone loss (367-373).
1.6.4. Age-related Osteoporosis and GH Administration
The effects of GH therapy on bone mineralization and bone turnover has been assessed in 
several studies involving subjects with primary osteoporosis. Many of these studies were of 
short duration, studied only a small number of patients and also involved co-administration of 
other bone active substances (374-377). GH therapy has been shown consistently to stimulate 
biochemical market's of bone turnover in models of primary osteoporosis, with increases in 
IGF-1 and IGF-BPs (258, 264, 267, 268, 272, 378-387). These initial studies were however, 
disappointing as a result of dose related side effects and limited benefit on BMD. In a 2-year 
study in older women with low bone mass rhGH increased bone density in the spine by 3% 
and lesser changes were observed in the hip. Radial and lumbar BMD increased in 8 elderly 
postmenopausal osteoporotic women 1 year after discontinuation of GH (380). GH treatment 
for 6 months increased lumbar BMD by 1.6% in elderly men (309).
Encouragingly, a more recent randomized placebo controlled study performed by Landin- 
Wilhelmsen et al. followed patients for 5 year's and showed GH to be well tolerated and 
beneficial with a delayed, extended and dose dependent effect resulting in almost a 15% 
increase in femoral and lumbar BMD (BMD) (388). All the patients in this study were given
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oestrogen replacement therapy, Ca and vitamin D. They were then randomly assigned to 
receive either placebo or GH at a dose of 1U (0.3mg) /day or 2.5U (0.8mg) /day. Maximum 
benefit was observed in the group administered the higher dose. A “catch up” effect, with an 
increase in BMD, 2 year's after the cessation of GH was observed as in previous studies (380). 
In contrast to previous studies in postmenopausal women, benefit was observed when GH, an 
anabolic agent, was combined with oestrogen, an antiresorptive agent (374).
Over and above the assessment of increases in bone turnover and BMD the underlying 
mechanisms by which GH effects these observed changes are less studied and even less well 
understood. Henneman et al. reported that GH administration for 1 day to 24 months 
produced a positive Ca balance and in a double-blind placebo-controlled study, daily high 
dose GHR given to 10 healthy individuals for 7 days resulted in a significant increase in 
serum Ca compared to placebo (389). In contrast GH treatment for 12 months in osteoporotic 
patients had no significant effect on total body Ca as assessed by neutron activation. No 
change in ionized Ca concentrations were observed in 8 postmenopausal women following 
short term (5 days) and sustained (5 weeks) rhGH administration. Studies have reported 
either a decrease or no change in PTH concentrations with differences dependent on GH 
dose. Similarly serum PO4 has been shown to increase, with an increase in TmPCVGFR by 
some but not others. Enhanced effect on PTH action with regard to renal la- hydroxylase 
activity with increasing l,25(OH)2D have been reported but so have unaltered l,25(OH)2 D 
and unaltered 24(OH)D (389). Limitations, including small numbers, single time point 
sampling methodology and co-administration of other agents with GH in these studies may 
be responsible for some of these discrepancies.
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The renewed interest in the use of GH in the treatment of osteoporosis with the demonstration 
of increased BMD with its long term use should allow a greater understanding into the role of 
GH in the pathophysiology of bone metabolism looking at effects on and interactions with 
PTH and phospho-calcium metabolism. The more widespread use of GH as replacement 
therapy in patients with AGHD and the recent effects of GH on PTH sensitivity and circadian 
rhythm in AGHD patients has also provided further insight into the mechanistic interactions 
between GH, PTH and phospho-calcium metabolism but whether these mechanisms are 
involved in the context of the physiological age related decline in GH and IGF- 
1 concentrations and age related bone loss needs further elucidation. To date there are no 
studies reporting the effects of GH on PTH secretory pattern, circadian rhythmicity and end- 
organ sensitivity in patients with age-related osteoporosis.
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Chapter 2 
Study Aims
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The aims of the studies in this dissertation were to provide a greater understanding of the 
underlying pathogenesis of age-related osteoporosis. The studies were designed to examine 
differences in bone mineral metabolism between older men and women with osteoporosis and 
control subjects; particularly changes in the GH/IGF-1 axis, PTH sensitivity, PTH circadian 
rhythm, phospho-calcium metabolism and biochemical markers of bone turnover. The effect 
of GH administration on bone metabolism in postmenopausal women with osteoporosis was 
also studied.
The study objectives were to determine:
1. Serum IGF-1 concentration, PTH sensitivity, PTH circadian rhythm, phospho-calcium 
metabolism and bone turnover in men and women in different age groups and with 
normal and low BMD.
2. The effects of GH administration on PTH sensitivity, PTH circadian rhythm, 
phospho-calcium metabolism and bone turnover in postmenopausal women with 
osteoporosis.
3. The relationship between PTH, OPG and [3CTX over a 24-hour period in 
premenopausal women and elderly postmenopausal women.
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Chapter 3
Methods
76
3.1. Subjects
3.1.1. Recruitment
Patients with low BMD and older control subjects with normal BMD were identified via a 
community osteoporosis screening program run by the Royal Liverpool University Hospital. 
The younger control men and premenopausal women were recruited from hospital personnel 
and from a database of volunteers willing to participate in medical research.
3.1.2. Patients and Controls
6 groups of subjects were recruited for cross-sectional comparison as detailed in Chapter 4. 
These included postmenopausal women and older men with low BMD as well as normal 
BMD. Younger men and premenopausal women were also recruited as healthy controls. 
Postmenopausal women with osteoporosis, who participated in the cross-sectional studies, 
were invited to participate in the longitudinal study detailed in Chapter 5.
3.1.3. Exclusion Criteria
The exclusion criteria are detailed in Table 3.1. Postmenopausal status was confirmed by 
serum FSH concentrations above 40U/L and absence of menstruation for at least 12 months.
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Table 3.1 Exclusion Criteria
Exclusion Crieria:
Diabetes
Severe cardiac, liver or renal disease 
Primary hyperparathyroidism 
Vertebral fracture 
Men with hypogonadism
Prescription of Bisphosphonate therapy prior to recruitment
Prescription of HRT or had been prescribed HRT in the year prior to start of the study
Prescription of calcium and vitamin D
Prescription of diuretics
Prescription of corticosteroids
Pregnancy
3.2. Biochemistry
3.2.1. Insulin-like Growth Factor 1
IGF-1 was measured with a specific radioimmunoassay (RIA) in the presence of a large 
excess of insulin like growth factor 2 (IGF-2) (Mediagnost, Tubingen, Germany) to block the 
interference of IGF-binding proteins (390). Intra- and interassay coefficients of variation
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(CVs) were 1.6 and 6.4% respectively. The samples for IGF-1 were sent to Germany and the 
assays were performed at the lab designated to run the IGF-1 assays for the hypopituitary 
control and complications study (HYPOCCS). Due to the overlap of IGF-1 concentrations 
across age groups, the IGF-1 concentrations were measured at the speciliast lab so as to 
provide mean concentrations with standard deviation scores (SDS) for age, based on normal 
ranges that were established with a cohort of 450 healthy adults (age 18-80 years; number of 
men = 225). The distribution of the values obtained was log normal, and consequently the 
measured values were log transformed before further calculations. Means and standard 
deviation (SD) of the log IGF-1 values were calculated for age intervals (10 years). Best fit 
regression curves were then derived for the means and mean minus SD that were separate for 
men and women under 28 years (polynomial 2nd degree) but since there was no significant 
difference in the measured variable after the age of 28 years, the values obtained for men and 
women were combined for 28 to 66.8 years and for >66.8 years (polynomial of 3ld degree). 
Standard deviation scores (SDS) were then calculated by: log (IGF-I) - mean/ SD. The mean 
was calculated as a function of age from the corresponding polynomial and SD was 
calculated by mean minus the value of the polynomial for the curve.
3.2.2. Calcium/ Phosphate/ Creatinine/ Albumin
Serum Ca, PO4, creatinine (Cr) and albumin were measured on all samples by the standard 
auto-analyser method (Roche Modular Systems (Incorporating the ISE1800, D2400, P800 
and El70), Roche Diagnostics, Lewes, U.K.). Serum Ca was adjusted for albumin (391). 
Serum ACa has been shown to strongly correlate with ionized Ca and has been found to be 
precise in subjects with Ca and albumin within the reference range (391, 392).
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Urine Ca, PO4 and Cr were analysed on all samples using standard laboratory methods 
(Roche Diagnostics, Lewes, UK). Urine values were expressed as molar ratios to creatinine 
(UUCa/Cr, UPCVCr) anc* as excretion per liter of creatinine clearance (CCr) by multiplying 
the urinary ratios and the serum creatinine to yield the urine calcium excretion (UCaE), urine 
phosphate excretion (UPO4E) respectively. The TmPCVGFR (mmol/L of GFR) was derived 
from the nomogram by Walton and Bijvoet (393).
3.2.3. Vitamin D
For the l,25(OH)2D assay, serum was treated with acetonitrile and the supernatant purified 
through C18-OH reverse phase column to obtain the fraction containing l,25(OH)2D which 
after evaporation was measured by radioimmunoassay (RIA) (Immune Diagnostic Systems 
(IDS) Ltd. Tyne and Wear, U.K.). Each sample contained tritiated l,25(OH)2D 1° act as a 
recovery. The intraassay CV was <9% and the interassay CV was <12% across the working 
range, with a detection limit of 15pmol/L, Serum 25(OH)D was measured using an RIA kit 
(DiaSorin, Inc., Stillwater,MN) after acetonitrile extraction. The intraassay CV was <8%, and 
the interassay CV was <11% across the working range, with a detection limit of 4nmol/L.
3.2.4. Parathyroid Hormone
Serum PTH (1-84) was measured on all samples using a commercial immunoradiometric 
assay (IRMA) (Nichols Institute, San Juan Capistrano, USA), with a detection limit of 
0.5pmol/L and intra- and inter-assay CVs of <7% across the working range.
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3.2.5. Plasma and Urine cyclic AMP
PcAMP was measured by RIA (BIOTRAC cAMP, Amersham Pharmacia Biotech, Little 
Chalfont, UK). The intraassay CV was <8%, the interassay CV was <10% across the working 
range, with a detection limit of 5nmol/L.
UcAMP was measured by in-house RIA methods as previously described (51, 394). The 
intra- and interassay CVs across the assay working range were <8% and 10% respectively, 
with a detection limit of 0.2^imol/L.
NcAMP, which is a reliable index of PTH activity at the level of the kidney (47), was 
determined from the formula:
NcAMP = (SCr x UcAMP/UCr)-PcAMP
NcAMP is expressed as nmol/L GFR, with serum creatinine (SCr) in pmol/L, UcAMP in 
pmol/L, urine creatinine (UCr) in mmol/L and PcAMP in nmol/L.
3.2.6. Markers of Bone Turnover
Serum concentration of pCTX, a marker of bone resorption, and PINP, a marker of bone 
formation, were measured using electrochemiluminesscence immunoassays (ECLIA) 
(ELECSYS, Roche Diagnostics, Lewes, UK). The intra- and inter-assay CYs for (3CTX were 
<4% and <5% respectively across the working range, with a detection limit of O.Olug/L and
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the intra- and inter-assay CVs for PINP, were <2% and <2.5% respectively across the 
working range, with a detection limit of 4pg/L.
3.2.7. Osteoprotegerin
OPG was measured by a direct sandwich-type enzyme linked immunoassay (Biomedica, 
Oxford Biosystems, UK) with a detection limit of 0.14 pmol/L and inter- and intra-assay CVs 
of less than 10% across the working range (0.14 pmol/L to 30 pmol/L).
3.3. Statistical Analysis
Statistical programs SPSS version 11.0 and CHRONOLAB 3.0 (Universdade de Vigo, Vigo, 
Spain) were used for analysis of the data. The numbers of patients required for the studies 
were calculated using two-sided significance levels of 0.05 and a power of 90% to detect a 
difference of l.Opmol/1 in PTH concentration, before and after GHR, with a standard 
deviation of 0.8.
3.3.1. GLM ANOVA for Repeated Measures
General linear model analysis of variance (GLM ANOVA) for repeated measures was used to 
analyse the data. Repeated measures analysis of variance (ANOVA) assumes normally 
distributed errors, equal variances and sphericity. The Kolmogorov-Smirnov test was used to 
confirm normal distribution and Levenes’s test for equality of variances. Mauchly’s test was
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used to confirm the sphericity assumption. If the assumption was violated, degrees of 
freedom were corrected using Greenhouse-Geisser estimates of sphericity.
3.3.2. Student’s t-test
Comparisons of normally distributed, paired and unpaired data were performed using 
student’s t-test. In all cases where this test was applied, a two-tailed hypothesis was used. 
Bonferroni’s correction method was applied to allow for multiple comparisons between visits 
before and after GH treatment.
3.3.3. Cosinor Rhythmometry
Individual and population mean cosinor analysis was used first to confirm circadian 
rhythmicity and determine the circadian rhythm parameters for PTH using CHRONOLAB 
3.0 (Universdade de Vigo, Vigo, Spain), a software package for analyzing biological time 
series by least squares estimation (51, 91, 395). The package has previously been well 
validated and used to analyse PTH and bone marker circadian rhythms in various groups of 
patients (51, 66, 91). The software thus provides the following circadian parameters: 1) 
midline estimate statistic of rhythm (MESOR), defined as the rhythm-adjusted mean or the 
average value of the rhythmic function fitted to the data; 2) amplitude, defined as half the 
extent of rhythmic change in a cycle approximated by the fitted cosine curve (difference 
between the maximum and MESOR of the fitted curve); and 3) acrophase, defined as the lag 
between a defined reference time (1400 h of the first day in our study when the fitted period 
is 24 h) and time of peak value of the crest time in the cosine curve fitted to the data. A p 
value for the rejection of the zero-amplitude (no rhythm) assumption is also determined for
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each individual series and for the group. The method used by the program allows analysis of 
hybrid data (time series sampled from a group of subjects, each represented by an individual 
series). Given k individual series, the program fits the same linear model with m different 
frequencies (harmonics or not from one fundamental period) to each series. This fit provides 
estimations for 2m + 1 parameters, namely, the amplitude and acrophase of each component, 
as well as the rhythm-adjusted mean. The population parameter estimates are based on the 
means of estimates obtained from individuals in the sample. The confidence intervals depend 
on the variability among individual parameter estimates. The variance-covariance matrix is 
then estimated on the basis of the sample covariances. Confidence intervals for the rhythm- 
adjusted mean, as well as for the amplitude-acrophase pair, of each component is then 
computed using the estimated covariance matrix. The p-values for testing the zero-amplitude 
assumption for each component, as well as for the global model is finally derived using those 
confidence intervals and the t and F distributions (396). Bingham’s test, developed for testing 
cosinor parameters and part of CHRONOLAB 3,0 software, was used to determine the 
significance of the differences of cosinor-derived circadian rhythm parameters between 
subjects.
Following the confirmation of concerted circadian rhythms further analysis of the more 
extensively studied PTH rhythm was performed as the next step. Over and above the diurnal 
valuation, the PTH rhythm has previously been demonstrated to have bimodal peaks in 
healthy individuals (early evening and nocturnal) and previous studies in pathological 
conditions have demonstrated alterations during the time periods of these peaks (51, 66, 91, 
94). Based on these previous data, time points for further analysis were selected for the 
individual peaks and using previously accepted techniques, we further analysed our data set. 
Based on recent work by Luboshitzky et al. the time of onset was defined as the time of first
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occurrence of at least 3 consecutive samples exceeding the mean levels of PTH obtained 
between 0800 h and 1400 h by more than 1 SD (397).
3.3.4. Cross-correlation Analysis
Cross-correlation analysis was performed to determine the relationships between the 24 h 
profiles of PTH, OPG and [3CTX in Chapter 6. Cross-correlation analysis determines the 
correlation between two time series of equal length that have been paired, data point by data 
point, and then one of the time series is shifted by one or more time points (lag time) and the 
correlation process is repeated. This process can be repeated with the time series shifted 
backward and forward, as many times as there are time points minus 1. PTH, OPG and (3CTX 
time series for the group were derived by calculating the mean value at each time point for all 
subjects (51, 74, 75, 91). Thus, 25 means were determined for PTH, OPG and (3CTX. To 
determine whether one time series led another, for instance whether changes in serum PTH 
preceded changes in OPG, we computed the cross-correlation functions at 12 lag time points 
(up to 12 h) (398). Previous studies using half hourly sampling have revealed significant 
interactions between PTH and other bone related metabolites using a 6 hour lag (51, 75, 91). 
To allow for the hourly sampling frequency and the lack of prior documentation of the 
circadian pattern of OPG we utilized a 12 hour lag time for cross correlation analysis.
Cross correlation with log transformed values and Monte Carlo simulation were performed to 
establish statistical replicability of the cross-correlation analysis between variables. In Monte 
Carlo simulation, statistical procedure was based on simulated samples of varying sizes (12, 
24 and 48, multiple of number of patients and controls) repeated 100 times. The type I error 
was estimated by samples consisting of time series representing healthy controls. For a type I 
error of 0.05, cut-off point of 5% was selected. To determine whether the time or lag
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difference between the original and simulated data was similar, z-score-transformed r values 
were obtained from each simulated sample. Significant cross-correlation values at any 
particular lag were then tested against the null hypothesis of purely random associations 
applied to the z-score-transformed r values, assuming that uncorrelated data show a unit 
normal z-score distribution with 0 mean unit-variances.
3.4. Measurement of Bone Mineral Density
BMD of the lumbar vertebrae (L2-4) and the FN was measured by DXA, using a Prodigy 
Oracle Fan-Beam bone densitometer (GE Medical Systems). DXA is the most widely used 
procedure for measuring bone mass and has been accepted as the gold standard (399). The 
measurements of BMD made by DXA are accurate and reproducible. The variability of 
repeat readings is <1% for the LS and <2% for the femur. Radiation exposure for DXA as 
minimal (clOmrem) and scanning time is short (5-20 minutes). T-scores were calculated 
against a reference population of UK subjects 20-39 years of age.
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Chapter 4
The Effect of Age. Bone Mineral Density and
Gender on Parathyroid Hormone Sensitivity. 
Parathyroid Hormone Circadian Rhythm, Phospho-
calcium Metabolism and Bone Turnover
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4.1 Introduction
The process of aging is associated with bone loss and an increasing incidence of osteoporosis. 
Peak skeletal mass is achieved between 20 and 25 years of age as reported in the majority of 
studies. (4-9)
Several anatomical studies (10, 11) and most cross-sectional densitometric studies (12-14) 
have demonstrated that after a transient period of stability, a slow phase of age related bone 
loss begins. This slow phase involves a linear, continued, steady, age-related annual loss of 
skeletal mass of about 0.5-1.0% in women and 0.3% in men that continues into old age (10, 
11, 15). The pattern of age related bone loss varies between genders and a biphasic pattern of 
bone loss has been identified in women, who undergo an accelerated transient phase of bone 
loss superimposed on the slow continuous phase, whereas men undergo only the protracted 
slow continuous phase (3, 16). It is this slow pattern of bone loss that results in what is 
referred to by some as type 2 or senile osteoporosis. The accelerated phase in women begins 
at the menopause and has been attributed to the cessation of ovarian function. This 
accelerated phase decreases over 5-10 years to merge again with the slow phase that 
continues indefinitely. A decrease in BMD into the osteoporotic range during the immediate 
postmenopausal period as a result of the increased bone resorption of the accelerated phase is 
referred to by some as type 1 osteoporosis.
The slow, lineai', age-related decline has been attributed to alteration of various age related 
factors including GH and IGF-1. Serum concentrations of GH and IGF-1 decrease with 
advancing age (274, 277, 278). This age related decrease is paralleled by a progressive loss 
of lean muscle mass and strength, a decline in physical performance, a decrease in quality of
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life, an increase in body fat and a decrease in BMD (285-289). These clinical features are also 
seen in AGHD(290). It has been hypothesized, therefore, that the ageing process and 
particularly age related or type 2 osteoporosis may be due to a relative GH deficient state (12, 
290-292). A relative GH deficiency has also been implicated in the development of 
postmenopausal or type 1 osteoporosis (290), as oestrogen is required for the secretion of GH 
(293). Thus GH and IGF-1 may have a role to play in the continuous slow phase bone loss 
with advancing age and a possible additional role in the superimposed rapid phase bone loss 
immediately after the menopause. The development of osteoporosis in men is less well 
studied than in women, especially in the absence of an andropause, equivalent to the 
menopause in women. In the majority of studies secondary causes for osteoporosis have been 
described and the causes of primary idiopathic osteoporosis in men and whether it really 
exists is still debated. The GH and IGF-1 axis (233, 400-403), PTH (52, 91), testosterone and 
oestrogen (303, 404-406) all contribute to the regulation of bone metabolism and 
maintenance of BMD in men.
Target organ insensitivity to the effects of PTH, altered PTH circadian rhythm and altered 
phospho-calcium metabolism are mechanisms that contribute to the development of 
osteoporosis in AGHD. These abnormalities are a consequence of the GH and IGF-1 
deficiency in patients with AGHD and can be reversed by GHR therapy. Given that the age 
related decline in GH and IGF-1 has been implicated in postmenopausal and age related bone 
loss, PTH insensitivity, altered PTH rhythm and abnormal phospho-calcium metabolism may 
also have a contributory role in these clinical settings. Thus, we investigated the differences 
in PTH sensitivity, PTH rhythm and phospho-calcium metabolism in men and women in 
different age groups with normal as well as low BMD.
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4.2. Subjects and Methods
4.2.1. Patient and Control Groups
We studied premenopausal women, postmenopausal women with normal BMD and 
postmenopausal women with low BMD. We also studied 3 groups of men referred to as 
younger men, older men with normal BMD and older men with low BMD. Number of 
subjects, mean age, LS (L2 - L4) and FN T-score are summarized in Table 4.1.
The younger men and premenopausal women were recruited from hospital personnel and 
from a database of volunteers willing to participate in medical research. Subjects with low 
BMD were newly diagnosed and identified via a community osteoporosis screening program. 
The study was approved by the Royal Liverpool University Hospital Ethics Committee and 
written informed consent was obtained from each patient prior to recruitment.
4.2.2. Bone Mineral Density
All subjects underwent bone densitometric evaluationas described in section 3.4. .
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4.2.3. Methods
All subjects were admitted to the Metabolic Bone Unit of the Royal Liverpool University 
Hospital at 1300h for a period of 25 hours. An indwelling venous cannula was inserted in the 
antecubital fossa of each patient at the time of admission, and blood samples were collected 
every half hour from 1400h on the day of admission to 1400h the following day. Samples 
were centrifuged immediately at -4°C, and serum/plasma was separated to be frozen at -70°C 
for later analysis. Subjects were provided with one and a half litres of water and encouraged 
to drink at fairly frequent intervals to maintain hydration and urine samples were collected at 
3-hourly intervals between 1400-2300h and 0800-1400h, and after estimating the volume of 
urine passed aliquots of these samples were stored at ~20°C for later analysis. A 24-hour urine 
volume estimation was made to ensure fluid balance was maintained and no significant 
variability was observed in the hydration of individuals. Subjects remained recumbent during 
2300-0800h and slept during this period. Each patient was served with standardised hospital 
meals at 0800, 1200, 1800 and 2200h. The serving sizes and combinations of foods contained 
recommended daily allowances of all nutrients including Ca and PO4.
4.2.4. Biochemistry
Analytes were measured using methods as described in section 3.2. Serum PTH, Ca, PO4 and 
albumin, concentration were measured on all 49 blood samples obtained from each 
individual. Serum IGF-1, 25(OH)D, l,25(OH)2D, pCTX and PINP concentration were 
measured on single time point 0900 samples. Urine calcium, phosphate and creatinine were 
measured on all urine samples. Pc AMP was measured on blood samples corresponding to the 
times of urine samples. NcAMP was calculated as described in section 3.2.5. The
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TmPCVGFR was calculated from the normogram derived by Walton and Bijvoet as 
described in section 3.2.2.
4.2.5. Statistical Analysis
Student’s t-test for unpaired data and GLM ANOVA for repeated measures were used, as 
described in section 3.3, wherever appropriate. PTH circadian rhythms were assessed as 
described in section 3.3.3. Values are expressed as means ± standard error of mean (SEM). P 
<0.05 was considered significant.
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4.3. Results
4.3.1. Age and BMD Dependent Differences in Women
4.3.I.I. IGF-1
IGF-1 concentration (Figure 4.1a) was significantly lower in the postmenopausal women with 
normal BMD (83.1±11.9pg/L, pcO.OOl) and low BMD (95.1±10.7pg/L, p<0.001) as 
compai’ed to the younger women (137.9±9.4|ig/L), with no significant difference between the 
2 groups of postmenopausal women (p=0.5).
4.3.I.2. PTH and NcAMP
24-h mean PTH concentration (Figure 4.1b) was higher in the postmenopausal women with 
normal BMD (4.7±0.1pmol/L, pcO.OOl) and highest in the women with low BMD 
(5.4±0.1pmol/L, pcO.OOl) when compai’ed with the premenopausal women (4.4±0.1pmol/L). 
The percentage increase in PTH concentration from premenopausal women to 
postmenopausal women with normal BMD was 6.8% and from premenopausal women to 
postmenopausal women with low BMD was 14.8%. The higher PTH in the postmenopausal 
women with normal BMD was associated with a trend toward a lower 24-h mean NcAMP 
concentration as compai’ed to the premenopausal women (22.8±1.6 nmol/L GFR versus 
18.4±3.1 nmol/L GFR, p=0.08, Figure 4.1c). The PTH concentration which was highest in the 
postmenopausal women with low BMD was associated with an even lower concentration of 
NcAMP (16.3±1.3 nmol/L GFR, p<0.05) which was significantly lower compai’ed to the
95
premenopausal women but not significantly different compared to the postmenopausal 
women with normal BMD.
4.3.1.3. PTH Circadian Rhythm
Individual and population cosinor analyses for circulating PTH (Figure 4.2) demonstrated 
significant circadian rhythms for all subjects in all 3 groups of women (p<0.001) but with 
subtle differences in the early evening and nocturnal peaks. The mean PTH MESOR was 
significantly higher in the postmenopausal women with low BMD than in the premenopausal 
women (5.4±0.4pmol/L versus 4.4±0.3pmol/L, p<0.05) with an intermediate MESOR value 
in the postmenopausal women with normal BMD which was not significantly different from 
the premenopausal women or the postmenopausal women with low BMD (Table 4.2). There 
was no significant difference in the amplitude or acrophase in all 3 groups (Table 4.2).
Circulating PTH demonstrated distinct early evening (time of onset 1400h) and nocturnal 
peaks (time of onset 2330h) in the premenopausal women. A more sustained increase in PTH 
concentration between 1400h and 2300h and a less pronounced nocturnal increase between 
2330h"0800h was observed in the postmenopausal women with normal as well as low BMD. 
The mean percentage change in PTH concentration between 1400h and 2330h [(value at each 
time point - 1400h value)/ 1400h value x 100] was significantly higher in the postmenopausal 
women with both normal BMD and low BMD when compared with premenopausal women 
(p<0.05) with no significant difference between the 2 groups of postmenopausal women 
confirming a more prolonged early evening rise. The nocturnal/early morning rise in PTH 
concentration (or maximum percentage increase in PTH concentration between 2330 and 
0800h [(maximum value between 2330-0800h - 2330h value)/2330h value x 100]) was
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significantly lower in both groups of postmenopausal women as compared to the 
premenopausal women (p<0.01) as was the mean percentage change in PTH concentration 
between 2330 and 0800h [(value at each time point - 2330h value)/ 2330h value x 100] 
(p<0.01) representing a less marked nocturnal peak. No significant difference was seen 
between the 2 groups of postmenopausal women with respect to the nocturnal peak.
4.3.1.4. Serum Adjusted Calcium
No significant difference in the 24-h mean ACa was observed in the three groups 
(premenopausal women, 2.34±0.003mmol/L; postmenopausal women with normal BMD, 
2.35±0.003mmol/L; postmenopausal women with low BMD, 2.35±0.003mmol/L; p=0.9; 
Figure 4. Id)
4.3.1.5. Serum Phosphate
24 hour mean serum PO4 concentration (Figure 4.1e) was significantly lower in the 
postmenopausal women with low BMD (1.09±0.01mmol/L, p<0.01) compared to the 
postmenopausal women with normal BMD (1.19±0.01mmol/L) and the premenopausal 
women (1.15±0.01mmol/L).
4.3.1.6. Vitamin D
25(OH)D (premenopausal women, 46±8nmol/L; postmenopausal women with normal BMD, 
45±8nmol/L; postmenopausal women with low BMD, 51±7nmol/L; p=0.5; Figure 4.If) and
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l,25(OH)2D concentrations (premenopausal women, 75±10pmol/L; postmenopausal women 
with normal BMD, 89±12pmol/L; postmenopausal women with low BMD, 78±12pmol/L; 
p=0.4; Figure 4. Ig) were not significantly different in all 3 groups of women.
4.3.1.7. Urine Calcium Excretion
UCa/Cr (0.6±0.03) and UCaE (Figure 4.1h) (0.04±0.003 mmol/L CCr) in the postmenopausal 
women with normal BMD and UCa/Cr (0.5±0.03) and UCaE (0.04±0.002 mmol/L CCr) in 
the postmenopausal women with low BMD were not significantly different (p=0.4) but were 
both significantly higher than in the premenopausal women (UCa/Cr 0.4±0.03; UCaE 
0,03±0.002 mmol/L CCr; p < 0.01).
4.3.1.8. Urine Phosphate Excretion
UPO4/C1* (3.0±0.14; p < 0.01) and UPO4E (Figure 4.1j) (0.24±0.010 mmol/L CCr; p < 0.01) 
were higher in the postmenopausal women with normal BMD when compared with 
premenopausal women (UP04/Cr 2.5±0.12; UPO4E 0.19±0.009 mmol/L CCr) and 
postmenopausal women with low BMD (UPCVCr 2.2±0.13; UPO4E 0.17±0.010 mmol/L 
CCr) with no significant difference between the latter 2 groups. No significant difference in 
the mean TmPCVGFR (Figure 4.1i) was observed within the 3 groups and was 0.98±0.02 
mmol/L GFR in the premenopausal women, 0.96±0.02 mmol/L GFR in the postmenopausal 
women with normal BMD and 0.95±0.02 mmol/L GFR in the postmenopausal women with 
low BMD but there was a trend towards a lower TmPCVGFR in the women with low BMD
(p=0.06).
98
4.3.I.9. Markers of Bone Turnover
There was a trend towards a higher |3CTX (Figure 4.1k) in the postmenopausal women with 
normal BMD (0.33±0.08 ug/L, p=0.08) when compared with the premenopausal women 
(0.20+0.06 ug/L) with a further significantly higher (3CTX concentration in the 
postmenopausal with low BMD (|3CTX 0.71+0.07 ug/L) when compared to the 
postmenopausal women with normal BMD (p<0.05). A trend towards a higher PINP (Figure 
4.11) concentration was also observed when the postmenopausal women with normal BMD 
(48.8+6.0pg/L) p=0.07) were compared to the premenopausal women (35.2±4.8gg/L) and the 
PINP concentration was significantly higher in the postmenopausal women with low BMD 
(57.3+5.2pg/L, p<0.05) when compared to the premenopausal women. There was however no 
significant increase when compared to postmenopausal women with normal BMD (p= 0.3). 
The ratio of circulating [3CTX to PINP was not significantly different in the postmenopausal 
women with normal BMD when compared to the premenopausal women but was significantly 
higher in the women with low BMD when compared to both the other groups (p<0.05).
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Figure 4.2. Cosinor-derived PTH circadian rhythms in young healthy premenopausal women, older 
postmenopausal women with normal BMD and older postmenopausal women with low BMD.
Smooth curved lines respresent best fit cosine curves, straight horizontal lines represent MESORs for each 
group and the vertical arrows mark the acrophase. Significant circadian rhythms were demonstrated for all 3 
groups with differences in MESOR, acrophase and amplitude. The MESOR was highest in postmenopausal 
women with low BMD with alterations to the rhythm that may be contributory to bone loss.
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4.3.2. Age and BMD Dependent Differences in Men
4.3.2.I. IGF-1
IGF-1 concentration (Figure 4,3a) was significantly lower in the older men with normal BMD 
(111.8±1 l.ljxg/L, pcO.OOl) and even lower in the older men with low BMD (76.8±12.8frg/L, 
pcO.OOl) as compared to the younger men (160.7±12.8pg/L), with the difference between the 
2 groups of older men approaching significance (p=0.055).
4.3.2.2. PTH and NcAMP
24-h mean PTH concentration (Figure 4.3b) was higher in the older men with normal BMD 
(5.1±0.07pmol/L, pcO.OOl) and highest in the men with low BMD (5.4±0.07pmol/L, 
pcO.OOl) when compared with the younger men (4.0±0.07pmol/L). The percentage increase 
in PTH concentration from younger men to older men with normal BMD was 27.5% and from 
younger men to older men with low BMD was 35.2%. The highest PTH concentration in the 
older men with low BMD was associated with a lower 24-h mean NcAMP concentration 
compared to younger men (25.7±3.4nmol/L GFR versus 18.4±2.1nmol/L GFR, pc0.05, 
Figure 4.3c). The older men with normal BMD with higher PTH concentration demonstrated 
an intermediate concentration of NcAMP (22.4±2.6nmol/L GFR, p=0.4) but with no 
statistically significant difference observed when compared with either the younger men or 
older men with low BMD.
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4.3.2.3. PTH Circadian Rhythm
Individual and population cosinor analyses for circulating PTH (Figure 4.4) demonstrated 
significant circadian rhythms for all subjects in all 3 groups of men (pcO.OOl) but with subtle 
differences in the early evening and nocturnal peaks. The mean PTH MESOR was 
significantly higher in the older men with low BMD than in the younger men (5.5±0.4 pmol/L 
versus 4.0±0.5 pmol/L, p<0.05) with an intermediate MESOR value in the older men with 
normal BMD (5.1 ±0.5 pmol/L) which was not statistically different from the younger men or 
the older men with low BMD. There was no significant difference in the amplitude or 
acrophase in all 3 groups (Table 4.2).
Circulating PTH demonstrated distinct early evening (time of onset 1400h) and nocturnal 
peaks (time of onset 2330h) in the younger men and older men with normal BMD similar to 
that observed in the premenopausal women. A more sustained increase in PTH concentration 
between 1400h and 2300h and a less pronounced nocturnal increase between 2330h-0800h 
was observed in the older men with low BMD similar to that seen in the postmenopausal 
women. The mean percentage change in PTH concentration between 1400h and 2330h [(value 
at each time point - 1400h value)/ 1400h value x 100] was significantly higher in the older 
men with low BMD when compared with the younger men and older men with normal BMD 
(p<0.05) with no significant difference between the latter 2 groups. The nocturnal/early 
morning rise in PTH concentration (or maximum percentage increase in PTH concentration 
between 2330 and 0800h [(maximum value between 2330-0800h - 2330h value)/2330h value 
x 100]) was significantly lower in older men with low BMD compared to the younger men 
and older men with normal BMD (p<0.01). Similar' differences in the mean percentage 
change in PTH concentration between 2330 and 0800h [(value at each time point - 2330h
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value)/ 2330h value x 100] were observed when the older men with low BMD were compared 
with the other 2 groups (p<0.01). These changes represented a less marked nocturnal peak. 
No significant difference was seen between the younger men and older men with normal 
BMD with respect to the nocturnal peak.
4.3.2.4. Serum Adjusted Calcium
24-h mean ACa was not significantly different in the 3 groups of men (younger men, 
2.35±0.003mmol/L; older men with normal BMD, 2.35±0.003mmol/L; older men with low 
BMD, 2.35±0.003mmol/L; Figure 4.3d).
4.3.2.5. Serum Phosphate
24 hour mean serum PO4 concentration (Figure 4.3e) was lower in the older men with normal 
BMD (1.08±0.02mmol/L, p<0.01) and in the older men with low BMD (1.07±0.02mmol/L, 
p<0.01) when compared with the younger men (1.19±0.02mmol/L) with no difference 
observed between the 2 groups of older men.
4.3.2.6. Vitamin D
25(OH)D (younger men 36±4 nmol/L; older men with normal BMD 36±4 nmol/L; older men 
with low BMD 42±5 nmol/L; p=0.5; Figure 4.3f) and l,25(OH)2D (younger men 
90±llpmoI/L; older men with normal BMD 83±llpmol/L; older men with low BMD 
98±10pmol/L; p=0.4; Figure 4.3g) concentrations were not significantly different among the 3 
groups.
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4.3.2.T. Urine Calcium Excretion
No significant difference was observed in the UCa/Cr (younger men 0.5±0.07, older men with 
normal BMD 0.5±0.07, older men with low BMD 0.5+0.06) or UCaE (Figure 4,3h) (younger 
men 0.04+0.006 mmol/L CCr, older men with normal BMD 0,04±0.006 mmol/L CCr, older 
men with low BMD 0.05+0.005 mmol/L CCr) in the 3 groups.
4.3.2.S. Urine Phosphate Excretion and TmPCVGFR
No significant difference in UPO4/C1' (younger men 2.4+0.15, older men with normal BMD 
2.1±0.15, older men with low BMD 2.4+0.13) and UPO4E (Figure 4.3j) was observed 
(younger men 0.21 ±0.02 mmol/L CCr, older men with normal BMD 0.20±0.02 mmol/L CCr, 
older men with low BMD 0.24+0.01 mmol/L CCr) was observed. TmPCVGFR (Figure 4.3i) 
was significantly different in all 3 groups and was lower in the older men with normal BMD 
(0.91+0.03 mmol/L GFR) and lowest in the older men with low BMD (0.82±0.02 mmol/L 
GFR, p<0,01) compared to the younger men (0.98±0.03 mmol/L GFR).
4.3.2.9. Markers of Bone Turnover
Both pCTX (Figure 4.3k) as well as PINP (Figure 4.31) concentrations were lower in the older 
men with normal BMD when compared with the younger men ([3CTX, 0.34±0.07 pg/L versus 
0.55±0.07 pg/L, p<0.05; PINP, 44.3±7.6pg/L versus 75.1±7.6pg/L, p<0.05) but the ratio of 
pCTX to PINP however was not significantly different in the 2 groups. The PINP
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concentration was also lower in the older men with low BMD (53.5±6.6tig/L, p<0.01) when 
compared to younger men but levels were similar to those in the older men with normal 
BMD. However the PCTX concentration in the older men with low BMD (0.63±0.06 pg/L) 
was higher than that observed in the older men with normal BMD (p<0.05) but similar to that 
in the younger men (p=0.6). The resulting ratio of [3CTX to PINP was significantly higher in 
the older men with low BMD as compared to younger men and older men with normal BMD 
(p<0.05).
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Figure 4.4. Cosinor-derived PTH circadian rhythms in young healthy men, older men with normal 
BMD and older men with low BMD.
Smooth curved lines respresent best fit cosine curves, straight horizontal lines represent MESORs for each 
group and the vertical arrows mark the acrophase. Significant circadian rhythms were demonstrated for all 3 
groups with differences in MESOR, acrophase and amplitude. The MESOR was highest in men with low 
BMD with alterations to the rhythm that may be contributory to bone loss.
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Table 4.2. PTH Circadian Rhythm Parameters [Mean(SEM)]
MESOR Ampitude Time of Peak
(pmol/L) (pmol/L) (h)
Premenopausal
Women
4.4(0.34) 0.5(0.10) 0106 (2404-0208)
Po stmenopausal 
women with 
normal BMD
4,8(0.40) 0.5(0.11) 0110(2357-0223)
Postmenopausal 
women with 
low BMD
5.4(0.37)* 0.6(0.10) 2344 (2239-2449)
Younger men 4.0(0.47) 0.6(0.12) 2307 (2213-2401)
Older men 
with
normal BMD
5.1(0.47) 0.6(0.12) 2418(2324-0112)
Older men 
with low
BMD
5.5(0.41)+ 0.7(0.10) 2203 (2117-2249)
* p<0.05 compared to premenopausal women
+ p<0.05 compared to younger men
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4.3.3. Gender Dependent Differences
4.3.3.I. Younger Men versus Premenopausal Women
24-h mean PTH concentration was lower in the younger men when compared with the 
premenopausal women (pcO.OOl; Figure 4.4b) with no significant difference in NcAMP 
concentration between the 2 groups (p=0.3; Figure 4.4c). Both (3CTX and PINP were 
significantly higher in younger men compared to premenopausal women (p<0.01; Figure 4.4k 
and Figure 4.41) but with no difference in the ratio of PCTX to PINP. No significant 
difference was observed in any of the other parameters except a trend towards a slightly 
higher serum PO4 concentration in men (p=0.08; Figure 4.4e).
4.3.3.2. Older Men with Normal BMD versus Postmenoapusal Women with 
Normal BMD
As opposed to the pattern seen in the comparison between younger men and premenopausal 
women, 24-h mean PTH concentration was found to be higher in the postmenopausal women 
with normal BMD as compared to the older men with normal BMD (p<0.05; Figure 4.4b) 
with no significant difference in NcAMP concentration between the 2 groups (p=0.6; Figure 
4.4c). Serum PO4 was also significantly higher in the postmenopausal women with normal 
BMD compared to the older men with normal BMD (pcO.OOl; Figure 4.4e) with no difference 
in other parameters except a trend towards higher TmPCVGFR (p=0.07) in the women 
compared to the men. No significant difference was observed in bone turnover markers 
between these 2 groups.
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4.3.3.3. Older Men with Low BMD versus Postmenoapusal Women with 
Low BMD
No difference in PTH, NcAMP, ACa, serum PO4, vitamin D metabolites and UCaE were 
observed between these 2 groups. There was a trend toward a higher UPO4E in the older men 
low BMD compared to the postmenopausal women with low BMD (p=0.07) with a 
significantly lower TmPCU/GFR in the men compared to the women (p<0.01). No significant 
difference in bone markers was seen between these 2 groups.
Figure 4.5. Gender Dependent Differences in Serum and Urine Biochemistry in younger 
subjects (premenopausal women versus younger men), older subjects with normal 
BMD (postmenopausal women with normal BMD versus older men with normal BMD)
Differences were demonstrated in (a) IGF-1, (b) PTH, (c) NcAMP, (d) ACa, (e) PO4, (f) 
25(OH)D, (g) l,25(OH)2D, (h) UCaE, (i) TmP04/GFR, (j) UPO4E, (k) pCTX, (1) PINP 
between men and women in the 3 different groups.
Women Men
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4.4. Discussion
The results of this study demonstrate that abnormalities in PTH sensitivity and circadian 
rhythm occur in postmenopausal women with low BMD as well as in postmenopausal 
women with normal BMD. These abnormalities are, however, more pronounced in 
postmenopausal women with low BMD than in postmenopausal women of a similar age 
with normal BMD. These abnormalities result in increased bone turnover and net bone 
loss. Abnormal PTH sensitivity and rhythm are therefore, part of the altered age related 
biochemical milieu in postmenopausal women and may contribute to the development of 
osteoporosis in postmenopausal women. We also observed decreased PTH sensitivity and 
altered PTH rhythm in older men with normal BMD as well as in older men with low 
BMD when compared with younger healthy control men. The degree of these 
abnormalities was greater in the older men with low BMD when compared to the older 
men with normal BMD suggesting that these abnormalities may contribute to the 
development of age related osteoporosis in men as well.
Various factors have been proposed as being determinants of an individual’s susceptibility 
to developing osteoporosis. Our findings suggest that differences in GH, IGF-1, PTH 
sensitivity and PTH circadian rhythm contribute to the differences in bone turnover in 
individuals. The bone turnover in individuals is also dependent on the the direct effect of 
gonadal hormones on bone as well as the changes that may occur in gonadal hormones 
with age. Gonadal hormones and age related changes in gonadal hormones may also affect 
bone indirectly by altering the effects of GH, IGF-1 and PTH on bone. As a consequence, 
these differences may determine an individual’s bone turnover and hence, risk of 
developing osteoporosis. Progressively lower circulating IGF-1 concentrations with
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significantly greater degrees of PTH insensitivity and rhythm abnormality amongst the 
groups studied would support the hypothesis that GH and IGF-1 contributes to PTH 
sensitivity and rhythm. We were able to demonstrate a significant difference in IGF-1 
concentration between the younger and older subjects. We were, however, unable to 
demonstrate a significant difference in IGF-1 between the postmenopausal women with 
low BMD and those with normal BMD. The difference in IGF-1 in the older men with 
normal and low BMD only approached significance. As this was a study involving 
circadian rhythm analysis the number of subjects in each group was limited. Circulating 
IGF-1 concentrations were compared using single time point measurements and the 
comparison was subject to type 2 error. IGF-1 concentrations have, however, been shown 
in larger population studies to be lower in individuals with low BMD compared to age 
matched controls with normal BMD (407-410). Furthermore, the measurement of IGF-1 in 
peripheral circulation may also not directly reflect the concentration of IGF-1 and other 
growth factors in the bone microenvironment which may also account for some of the 
differences observed between individuals with normal and low BMD of the same gender 
and similar age. Lower concentrations of IGF-1 and other growth factors in the bone 
microenvironment may be responsible for the uncoupling of turnover in individuals with 
low BMD. Other factors including bio-available estradiol, cytokines such as OPG, 
RANKL, peak bone mass achieved in adult life, preexisting life style factors or a genetic 
predisposition may all contribute, individually or more likely in combination, to 
determining which individuals develop abnormal bone turnover and lower BMD.
Gender is, inherently, a determinant of the risk of developing osteoporosis; as men and 
women differ fundamentally in the aging process due to the occurrence of the menopause 
in women with no natural male equivalent. Loss of oestrogen restraint of osteoclasts.
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following the menopause, results in an increase in bone resorptive activity. This should be 
followed by an increase in osteoblast activity due to the coupling of resorption to 
formation. Our data confirms that bone turnover is higher in postmenopausal as compared 
to premenopausal women. The increase in bone turnover was, however, of a lesser 
magnitude in postmenopausal women with normal BMD compared to those with low 
BMD. This lesser increase in bone turnover occurred such that the ratio of resorption to 
formation markers was not statistically different from that observed in the premenopausal 
women. This would suggest that despite an increased activation frequency, resorption may 
have, at least at the time of being studied, remained sufficiently coupled to formation. This 
could explain the absence of a reduction in BMD in these postmenopausal women. In the 
women with low BMD, however, the greater increase in bone turnover was associated with 
an increase in the ratio of resorption to formation markers suggesting an element of 
uncoupling of bone turnover which would contribute to bone loss and a low BMD.
Previous studies using various techniques, including histomorphometry and 3-dimensional 
micro-computed tomography, have suggested that even without demonstrated decreases in 
BMD postmenopausal women do demonstrate bone loss at a micro architectural level (411, 
412). We utilized biochemical markers of bone turnover from peripheral circulation to 
measure bone turnover. It is possible that the lesser increase in turnover markers in the 
postmenopausal women with normal BMD was not of sufficient magnitude to allow us to 
appreciate a change in the ratio of bone resorption to formation markers as was observed in 
the postmenopausal women with low BMD. This may have been a consequence of type 2 
error. It is also possible that the women with normal BMD may have been studied at a 
stage following the onset of menopause when bone turnover may have increased but bone 
loss may not have become evident. In time, these women may develop changes similar to
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that seen in the women with low BMD and eventually demonstrate a reduction in BMD 
themselves.
The men we studied demonstrated a distinctly different pattern to the women. The bone 
turnover in the older men with normal BMD was lower than in the younger men (369, 
370). The pattern is in keeping with previous studies in men that have shown a decrease in 
biochemical bone markers until the age of 60 (369). We also observed no difference in the 
resoprtion to formation ratio, suggesting that despite a low bone turnover state in the older 
men with normal BMD, coupling may be maintained. This may account for the preserved 
BMD in these older men. After the age of 60 years, markers of bone formation remain 
stable while resorption markers show a variable increase with aging and there is an inverse 
relationship between bone turnover and BMD (369). We observed a significant increase in 
the resorption to formation ratio in the men with low BMD, suggesting uncoupling of bone 
turnover that would contribute to the development of a low BMD in these men.
We, thus, observed distinct differences in the pattern of change in bone turnover with age 
and BMD between men and women. Our findings also suggest that the increase in bone 
turnover, degree of uncoupling and development of low BMD are not uniform or 
predictable consequences of advancing age. Individuals of a similar age over 60 
demonstrate differences in bone turnover and BMD that are the result of differences in 
various contributory factors including GH, IGF-1, PTH sensitivity and PTH rhythm.
Altered PTH sensitivity contributes to the development of osteoporosis in patients with 
AGHD and GHR therapy improves PTH sensitivity and has a restorative effect on PTH 
rhythm (91). There is, however, a gender based difference in the benefit derived from GHR
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therapy. Women with AGHD who are receiving oestrogen replacement demonstrate a 
smaller increase in PTH sensitivity and a less marked effect on PTH rhythm following GH 
replacement therapy as compared to men with AGHD receiving testosterone replacement 
therapy (93). It is well established that gonadal steroids modify the metabolic effects of 
GH and whilst androgens potentiate the effects of GH at a peripheral level, oestrogens 
antagonize the effects (276, 281, 413, 414). This would suggest that younger 
premenopausal women who are oestrogen replete would be more PTH resistant than 
younger men who are testosterone replete in the presence of similar' GH and IGF-1 
concentrations. Our observation of a higher PTH concentration in the younger 
premenopausal women when compared to the younger men with similar' NcAMP 
concentrations would be in keeping with this.
The pattern of decline in gonadal steroids with age differs in men and women. In women, 
the acute decline in oestrogen concentrations following the menopause would theoretically 
be paralleled by an acute decrease in the antagonistic effect of oestrogen on GH and IGF-1 
action. The gradual decline in testosterone in men, however, would be paralleled by a 
gradual decrease in the potentiating effect of testosterone on GH and IGF-1 action. We 
observed a smaller percentage increase in PTH concentration from younger premenopausal 
women to older postmenopausal women possibly as a result of the acute decline in 
oestrogen related antagonism of GH and IGF-1 in the postmenopausal women resulting in 
less PTH resistance. A greater percentage increase in PTH concentration from younger 
men to older men may be the result of the continuous decline in potentiation of GH and 
IGF-1 and hence relatively more marked increase in PTH resistance.
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A further sequence of events may also be postulated. Initially, the acute decline in 
oestrogen in postmenopausal women would result in two simultaneous changes: an 
increase in osteoclast resorption and a decrease in antagonism of GH and IGF-1. This may 
allow GH and IGF-1 to act on osteoblasts to increase bone formation in an attempt to meet 
the demands of increased resorption. This would result in the increased bone turnover seen 
in postmenopausal women. In men, on the other hand, the steady decline in bio-available 
testosterone with age should result in a steady decline in the anabolic effect of GH and 
IGF-1. With no acute catabolic stimulus, like the oestrogen deficiency in postmenopausal 
women, one would expect a gradual decrease in bone turnover as was observed in the older 
men with normal BMD.
In the men with low BMD however, we did see an increase in bone resorption with a lesser 
increase in bone formation. This pattern was similar to that seen in postmenopausal women 
suggesting that bone turnover in these individuals was uncoupled. In postmenopausal 
women oestrogen withdrawal is the most obvious catabolic stimulus resulting in increased 
resorption but the catabolic stimulus in men is still unclear. Age related decline in both 
testosterone as well as oestrogen can directly result in increased resorption and have both 
been implicated in the development of osteoporosis in men (406). It has also been 
proposed that lower IGF-1 may potentially increase SHBG, result in lower bio-available 
sex steroid concentrations and therefore indirectly increase bone resorption (406). As bio- 
available testosterone dwindles and the balance shifts towards oestrogen this could also 
result in decreased potentiation and increased antagonism of the anabolic effect of GH and 
IGF-1 resulting in uncoupling. We analysed total testosterone concentrations in the older 
men we studied. All the men had concentrations that were in the normal reference range.
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However, his does not account for individual differences in bio availability of androgens or 
bio-available oestrogen either.
The effect of PTH rhythm on bone turnover is well established (64, 65, 415). PTH rhythm 
was abnormal in the older men with low BMD but remained intact in the men with normal 
BMD. PTH rhythm was also abnormal in the postmenopausal women with normal BMD 
and the postmenopausal women with low BMD. Thus abnormal PTH rhythms were 
observed in the same 3 groups that also had increased resorption markers. This would 
suggest that the abnormal secretory pattern of PTH may very well be a contributory 
catabolic stimulus contributing to the increased resorption in these groups. The loss of 
oestrogen is the predominant stimulus for increased resorption in postmenopausal women 
but abnormal PTH rhythmicity may also contribute. The mechanisms for bone loss in men 
are less well understood and our findings suggest that abnormal PTH rhythmicity may be 
involved.
PTH has a phosphaturic effect and renal insensitivity to the effects of PTH would result in 
an attempt to retain PO4. GH modulates renal PO4 handling via IGF-1, independently of 
PTH or l,25(OH)2D (131, 135) and a low IGF-1 results in a decrease in TmPCVGFR and 
hence increased phosphaturia (131, 416). Gender dependent differences in renal PO4 
handling have also been suggested in patients with AGHD (93). PO4 concentrations and 
TmPCVGFR were low in both groups of older men as compared to younger men, whereas 
low PO4 concentration was observed only in the women with low BMD with the difference 
in TmPCVGFR approaching significance. Thus, there was a decrease in serum PO4 and 
TmPCVGFR in the older individuals despite increasing PTH resistance in these 
individuals. This would suggest that the effect of the lower IGF-1 concentrations on renal
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PO4 handling outweighs the effect of PTH in these individuals. The effects on PO4 
handling with age were more marked in the men than in the women. This may have been a 
reflection of the greater decrease in IGF-1 concentration in the men as compared to 
women. It could also have been the greater manifestation of the effects of the declining GH 
and IGF-1 in men as described earlier with respect to the pattern of decline in gonadal 
hormones.
A defect in renal Ca conservation has also previously been observed in postmenopausal 
women with osteoporosis and has been attributed to the lack of oestrogen following the 
menopause (67). It was postulated that the defect in renal Ca conservation was a primary 
catabolic stimulus. The increase in bone turnover in postmenopausal women was 
considered a mechanism to compensate for the renal Ca loss by releasing Ca from the 
skeletal reservoir. The postmenopausal women we studied also had a higher Ca excretion 
compared to the premenopausal women. This abnormality in renal Ca conservation could 
also be explained, at least in part, by renal insensitivity to the Ca conserving effects of PTH 
in these women. Alternatively a primary increase in bone resorption and Ca release from 
bone may result in an increased filtered load and subsequent increased urine excretion.
Despite a greater increase in PTH resistance in the older men when compared to the 
postmenopausal women, Ca excretion was no different in the older men when compared to 
the younger men. It is possible that oestrogen deficiency does have a role in regulating 
renal Ca conservation and hence men are less affected. The increase in bone turnover in 
older men was less than in the postmenopausal women. If the increase in bone turnover 
was the primary event then there would have been no increase in the filtered load and 
hence no increase in UCa excretion. Although the concentrations of 25(OH)D and
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l,25(OH)2D were similar in all groups studied, they were in the low normal range and this 
may also have affected Ca and PO4 metabolism in addition to effects on individual 
differences in PTH, bone turnover and BMD.
In conclusion, bone loss in older men and women is associated with target organ 
insensitivity to PTH, abnormal PTH circadian rhythm and abnormal bone mineral 
metabolism. There are distinct differences between men and women as consequence of the 
differential effects of oestrogen and testoseterone. There are also differences because men 
and women differ distinctly in the way that gonadal hormones change with age. Abnormal 
PTH sensitivity and rhythm were associated with declining IGF-1 concentrations in 
postmenopausal women and older men. Abnormal PTH sensitivity and rhythm may be 
consequences of the low IGF-1 in these patients as in patients with AGHD. We propose 
that our observations add a further component to the understanding of the extremely 
complex interplay of biochemical and hormonal factors that regulate bone metabolism in 
postmenopausal women and older men.
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Chapter 5
The Effect of Growth Hormone on Parathyroid
Hormone Sensitivity, Parathyroid Hormone
Circadian Rhvthmicitv. Phospho-calcium
Metabolism and Bone Turnover in 
Postmenopausal Women with Osteoporosis
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5.1. Introduction
Bone loss and the increasing incidence of osteoporosis is an accompaniment of aging. 
Women undergo two phases of bone loss - a slow phase with a linear decrease in bone, 
continuing into old age and a superimposed, accelerated transient phase beginning at 
menopause caused by oestrogen deficiency (11, 14, 417). The slow phase in the 
development of osteoporosis has been attributed to alteration of age related factors 
resulting in impaired osteoblast function and bone formation. These include GH and IGF- 
1, both major determinants of adult bone mass (418, 419), that decrease with advancing 
age (277-283) and are lower in women with established osteoporosis (407).
The beneficial effects of GH on bone metabolism and BMD have been demonstrated in 
AGHD patients (91, 420). Target organ insensitivity to the effects of PTH resulting in 
increased circulating PTH and abnormal PTH secretion (51) contributes to the 
development of osteoporosis in AGHD. GHR in AGHD patients has been shown to 
increase bone and renal PTH receptor or target cell sensitivity to the effects of PTH and 
simultaneously restore PTH secretory rhythm, increase bone turnover markers, 
l,25(OH)2D concentration and Ca absorption/reabsorption, thus contributing to the 
positive effects of GH on bone (91).
Postmenopausal women with osteoporosis have high circulating PTH concentrations with 
abnormal PTH circadian rhythm (66, 67) and may consequently be insensitive to the 
effects of PTH (53-55). The decline in GH/IGF-1 with aging may contribute to these PTH 
related abnormalities via mechanisms similar to that observed in untreated AGHD (51,91). 
GH has been previously administered to healthy elderly women and women with
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postmenopausal osteoporosis and increases in bone turnover and bone density have been 
demonstrated (378, 385, 388). However, the mechanisms by which GH exerts its 
beneficial effects on bone in established postmenopausal osteoporosis remain unexplained. 
We therefore investigated the effects of 12 months of GH administration on PTH secretory 
pattern, PTH sensitivity and bone mineral metabolism in postmenopausal women with 
osteoporosis.
5.2. Subjects and Methods
5.2.1. Patients and Controls
Fourteen postmenopausal women (mean ± SEM: 63.4±2.1 years, range 52-79 years), 
newly diagnosed with osteoporosis, were recruited from a community osteoporosis 
screening program. The mean BMD T score ± SEM in the (LS (L2-L4) and FN was - 
3.3±0.2 and -2.0±0.2 respectively. For baseline comparison 14 healthy premenopausal 
control women (33.9 ± 2.2 years, range 25 - 39 year's) with normal BMD (LS and FN T 
score was 0.3 ± 0.3 and 0.6 ± 0.2 respectively) were recruited from a database of 
volunteers willing to participate in medical research.
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Table 5.1. Demographic Characteristics of Patients and Controls
[Mean(SEM)]
Osteoporotic
women
Control
subjects
n 14 14
Age (years) 63.4(2.0)** 33.9(2.2)
Height (m) 1.60(0.02) 1.63(0.02)
Weight (kg) 63.2(3.0) 70.7(3.1)
BMI (kg/m2) 24.9(1.2) 26.8(1.2)
Waist/hip ratio 0.84(0.02) 0.85(0.02)
Fat Mass (kg) 21.6(2.3) 25.6 (2.5)
Fat Percentage (%) 33.26 (2.37) 34.32 (2.56)
IGF-I (ng/ml) 102.8(10.0) * 140.9(10.8)
IGF I SDS -1.21(0.26) -1.19(0.28)
BMD (T - score)
Lumbar spine -3.3(0.2) *** 0.3(0.3)
Femoral neck -2.0(0.2) *** 0.6(0.2)
p<0.05 osteoporotic women compared to control subjects 
p<0.01 osteoporotic women compared to control subjects 
pcO.OOl osteoporotic women compared to control subjects
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5.2.2. Methods
Study visits occurred as documented in section 4.2.3. Baseline samples were collected in 
all controls and subjects with osteoporosis at the initial study visit, following which GH 
(Humatrope, Eli Lilly & Co., Basingstoke, Hampshire, UK) was commenced at a standard 
daily dose of 0.2mg, self-injected using an automated pen device (Humatrope-Pen II, Eli 
Lilly & Co., Basingstoke, Hampshire, UK) at 2200h every night only in the subjects with 
osteoporosis. GH was initiated at 0.2 mg/day for four weeks and then titrated by 
increments of 0.1 mg/day every 2 weeks, according to insulin-like growth factor 1 (IGF-1) 
concentration. We aimed for a target IGF-1 concentration within ±1 SD of the median 
IGF-1 for a woman age 45 years. Study visits were repeated 1,3,6 and 12 months after the 
initiation of GH and all patients completed the 12 month study. The local ethics committee 
approved the study, and written informed consent was obtained from each patient before 
recruitment.
5.2.3. Bone Mineral Density
All subjects underwent bone densitometric evaluation as described in section 3.4.
5.2.4. Biochemistry
Analytes were measured using methods as described in section 3.2. Serum PTH, Ca, PO4 
and albumin, concentration were measured on all 49 blood samples obtained from each 
individual at every visit. Serum IGF-1, 25(OH)D, l,25(OH)2D, pCTX and PINP 
concentration were measured on single time point 0900 samples at every visit. Urine 
calcium, phosphate and creatinine were measured on all urine samples at every visit.
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PcAMP was measured on blood samples corresponding to the times of urine samples. 
NcAMP was calculated as described in section 3.2.5. The TmPCVGFR was calculated 
from the normogram derived by Walton and Bijvoet as described in section 3.2.2.
5.2.5. Statistical Analysis
General lineal’ model analysis of variance (GLM ANOVA) for repeated measures was used 
to analyse the data as described in section 3.3.1. Mauchly’s test indicated that the 
sphericity assumption was violated and degrees of freedom were corrected using 
Greenhouse-Geisser estimate of sphericity (8=0.53). This method has been validated for 
similar’ comparisons (51, 93). Student’s t-test for unpaired data was used to determine the 
significance of the differences between premenopausal and postmenopausal women. PTH 
circadian rhythms were assessed as described in section 3.3.3. Values are expressed as the 
mean ± standard error of mean (SEM).
5.3. Results
5.3.1. GH Dose and IGF-1
IGF-I concentration (Figure 5.1a) was significantly lower in the women with osteoporosis 
compared to the controls (101.5±8.9pg/L versus 140.9±10.8pg/L; p<0.05). In the treated 
patients the mean GH dose (Figure 5.1b) was 0.2±0.01 mg/day at 1 month and increasing 
to 0.39±0.01 mg/day at 3 months (pcO.OOl) and further titrated to 0.56±0.04 mg/day at 6 
months (p<0.001 compared to baseline; p<0.01 compared to 3 months). Maximum dose 
was achieved at 6 months in all patients and further increases were not tolerated. 3 patients 
had dose reductions from 6 months to 12 months due to increased musculo-skeletal pains.
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The mean GH dose was 0.49±0.05 mg/day at 12 months (p<0.001 compared to baseline; 
p<0.05 compared to 3 months; no significant difference compared to 6 months). Mean 
serum IGF-I increased significantly from 101.5±8.9pg/L to 128.3+12. l[ig/L by 1 month 
(p<0,001), 157.2+15.8^ig/L at 3 months (pcO.OOl), 172.9±13.6[ig/L at 6 months (pcO.OOl, 
compared to baseline; p=0.06, compared to 3 months) and 166.9±14.8p,g/L at 12 months 
(pcO.OOl, compared to baseline; p=NS, compared to 3 and 6 months). Similarly IGF-I SDS 
increased from -1.26 + 0.27 at baseline to -0.62± 0.29 at 1 month (pcO.OOl), -0.03+ 0.26 at 
3 months (pcO.OOl) 0.28± 0.26 at 6 months (pcO.OOl, compared to baseline; p=0.07, 
compared to 3 months) and 0.19 ± 0.26 at 12 months (pcO.OOl, compared to baseline; 
p=NS, compared to 3 and 6 months).
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5.3.2. PTH
24-h mean PTH concentration (Figure 5.2a) was higher in the osteoporotic women (5.4 ± 
0.1 pmol/L) than in healthy controls (4.4± 0.1 pmol/L, pcO.OOl). Following GH 
administration 24-h mean PTH concentration decreased progressively from baseline (5.4 ± 
0.1 pmol/L) to 1 (5.2 ±0.1 pmol/L, pcO.OOl), 3 (5.0 ±0.1 pmol/L, pcO.OOl) and 6 months 
(4.7 ±0.1 pmol/L, pcO.OOl) with maximum reduction in PTH concentration at 6 months. 
PTH concentrations then increased significantly by 12 months (4.9 ± 0.1 pmol/L, p<0.05 
compared to 6 months) but remained below baseline concentrations.
5.3.3. NcAMP
NcAMP (Figure 5.2b) was significantly lower in osteoporotic women (17.2 ±1.2 nmol/L 
GFR) as compare to controls (21.4 ± 1.4 nmol/L GFR, p<0.05). NcAMP increased 
following 1 month of GH administration (24.2 ± 2.5 nmol/L GFR, p<0.05) and remained 
elevated at 3 months (27.3 ± 1.5 nmol/L GFR, pcO.OOl) and 6 months (32.4 ± 2.5 nmol/L 
GFR, pcO.OOl) compared to baseline (17.2 ±1.2 nmol/L GFR) and returned to levels not 
significantly different to baseline at 12 months (14.8 ± 1.6 nmol/L GFR).
5.3.4. Serum Adjusted Calcium
24-h mean ACa concentration (Figure 5.2c) was not significantly different in the 
osteoporotic women (2.36 ± 0.004 mmol/L, pc0.05) as compared to controls (2.35 ± 0.004 
mmol/L). The 24-h mean ACa concentration increased progressively following 1 month 
(2.40 ± 0.002 mmol/L, pcO.OOl) and 3 months (2.38 ± 0.004 mmol/L, pcO.OOl) of GH
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compared to baseline (2.36 ± 0.004 mmol/L) but returned to concentrations that were not
significantly different from baseline at 6 months (2.35 + 0.002 mmol/L) and 12 months 
(2.34 ± 0.002 mmol/L).
5.3.5. Serum Phosphate
24-h mean PO4 concentration (Figure 5.2d) was lower in osteoporotic women (1.11 + 0.01 
mmol/L, p<0.05) as compared to controls (1.15 ± 0.01 mmol/L). 24-h mean PO4 
concentration increased progressively after 1 (1.18 ± 0.01 mmol/L), 3 (1.23 ± 0.01 
mmol/L) and 6 months (1.27+ 0.01 mmol/L) and remained elevated with no further 
increase at 12 months (1.28± 0.01 mmol/L) of GH administration compared to baseline 
(1.11 +0.01 mmol/L, p<0.001).
5.3.6. Vitamin D
No significant difference in serum 25(OH)D concentration was observed between controls 
(42.0 + 6.1 nmol/L) and osteoporotic women (47.6 ±6.1 nmol/L, p=0.53). 25(OH)D 
concentrations were not significantly different following 1 (45.1 ± 4.2 nmol/L), 3 (49.9 ± 
5.3 nmol/L) and 12 (42.2 + 4.8 nmol/L) months of GH administration. An increase was 
observed at 6 months (54.5 ± 4.5 nmol/L, p<0.05) as compared to baseline (47.6 ± 3.6 
nmol/L). No significant difference in serum l,25(OH)2D concentration was observed 
between controls (74.0 ± 8.2 pmol/L) and osteoporotic women (78.1 + 8.2 pmol/L, p=0.73) 
(Figure 5.2e). l,25(OH)2D concentrations increased by 3 months (99.4 ± 10.0 pmol/L,
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pcO.OOl) and were maintained at 6 (95.7 ± 9.5 pmol/L, p<0.05) and 12 months (99.9 ±11.6 
pmol/L, p<0.01) (Figure 5.2e).
5.3.7. Urine Calcium Excretion
UCa/Cr (0.6±0.03 versus 0.4±0.03; p < 0.001) and UCaE (Figure 5.2f) (0.05±0.002 versus 
0.03±0.002 mmol/L CCr; p < 0.001) were higher in the osteoporotic women compared to 
controls. UCa/Cr increased following 3 (0.8±0.04; p < 0.001) and 6 (0.9+0.04; p < 0.001) 
months of GH and was not significantly different at 1 (0.7±0.04; p = 0,1) and 12 months 
(0.7±0.04; p = 0.2) as compared to baseline (0.6±0.03). UCaE also increased similarly 
(Baseline 0.05±0.002 mmol/L CCr; 1 month 0.06±0.003 mmol/L CCr, p=NS; 3 months 
0.07±0.003 mmol/L CCr, pcO.OOl; 6 months 0.08±0.003 mmol/L CCr, pcO.OOl; 12 
months 0.06±0.003 mmol/L CCr, p=NS)
5.3.8. Urine Phosphate Excretion and TmPCVGFR
UP04/Cr (2.2±0.12 versus 2.5±0.12; p = 0.1) and UPO4E (Figure 5.2g) (0.18±0.009 
mmol/L CCr versus 0.19±0.009 mmol/L CCr; p = 0.3) were not significantly different in 
the 2 groups. UPCVCr increased significantly following 1(2.8±0.15; p < 0.001), 3 
(3.2±0.16; p < 0.001), 6 (3.3±0.17; p < 0.001) and 12 months (2.7±0.13; p < 0.05) of GH 
as compared to baseline (2.2±0.12) with similar increases in UPO4E (Baseline 0.18±0.009 
mmol/L CCr; 1 month 0.22±0.012 mmol/L CCr, pcO.OOl; 3 months 0.25±0.012 mmol/L 
CCr, pcO.OOl; 6 months 0.28±0.014 mmol/L CCr, pcO.OOl; 12 months 0.21 ±0.012 
mmol/L CCr, pc0.05).
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TmPCVGFR (Figure 5.2h) was not significantly different between controls (0.98 + 0.02 
mmol/L GFR) and osteoporotic women (0.96 ± 0.02 mmol/L GFR, p=0.6). TmPO^GFR 
increased following GH administration for 1 month (0.99 ± 0.02 mmol/L GFR, p<0.05) 
and remained elevated at 3 (0.99 + 0.02 mmol/L GFR, p<0.05), 6 (1.01 ± 0.02 mmol/L 
GFR, pcO.001) and 12 (1.08 ± 0.02 mmol/L GFR, p<0,001) months compared to baseline.
5.3.9. Markers of Bone Turnover
(3CTX concentrations (Figure 5.2i) were significantly higher in osteoporotic women (0.74± 
0.07pg/L) as compared to controls (0.20+ 0.07pg/L, p<0.001). Following GH 
administration (3CTX concentrations increased progressively from baseline (0.74± 
0.07pg/L) to 1 (0.83+ 0.07[xg/L, p<0.05) and 3 months (1.07+ 0.09|ig/L, pcO.001) with no 
further increase seen at 6 (1.18± O.lOpg/L, p<0.001 compai-ed to baseline) and 12 months 
(1.08+ 0.12pg/L, pcO.001 compai'ed to baseline).
PINP (Figure 5.2j) concentrations were significantly higher in osteoporotic women (60±5 
pg/L) as compai'ed to controls (35±5 pg/L, p<0.01). PINP concentrations increased 
progressively from baseline (60±5 pg/L) to 1 (69+5 pg/L, p<0.001), 3 (93±6pg/L, 
p<0.001) and 6 months (126±11 pg/L, p<0.001). The increase was maintained following 
12 months (122+14 pg/L, p<0.001) of GH administration.
The percentage increase in PINP concentration was significantly higher than pCTX 
following 6 (76±25% vs. 142±25%, p<0.05) and 12 months (61±25% vs. 133±25%, 
p<0.05) of GH administration.
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5.3.10. PTH Circadian Rhythmicity
Individual and population cosinor analyses for circulating PTH (Figures 5.3 and 5.4) 
demonstrated significant circadian rhythms for all healthy controls and all osteoporotic 
patients at all visits (pcO.OOl) but with differences between patients and controls and 
changes following GH administration. The mean PTH MESOR was significantly higher in 
the osteoporotic women than in the controls (5.4±0.3pmol/L versus 4.4±0.3pmol/L, 
p=0.03), but there was no significant difference in the amplitude (0.7±0.1pmol/L versus 
0.5±0.1pmol/L for osteoporotic women and controls respectively, p=0.22) or acrophase (- 
156±16 degrees versus -178±16 degrees for osteoporotic women and controls respectively, 
p=0.36). Following GH administration to the osteoporotic women, mean PTH MESOR 
decreased by 3 months (5.0 ± 0.3 pmol/L, p<0.05) with a further decrease at 6 months (4.5 
± 0.2 pmol/L, pcO.OOl) when maximum reduction in mean PTH MESOR was observed. 
PTH MESOR then rose significantly by 12 months (4.9 + 0.1 pmol/L, p<0.05 compared to 
6 months) but remained below baseline (5.3 + 0.3 pmol/L, p<0.05). The amplitude and 
acrophase of the PTH circadian rhythm did not change significantly following GH 
administration. A reduction in mean percentage increase (421-423) in PTH concentration 
between 1400-2300h, without significant change in the maximum percentage increase 
(424) indicated a narrower afternoon/evening peak, following 3, 6 and 12 months of GH 
administration. The maximum percentage increase and the mean percentage change in 
PTH concentration between 2330 and 0800h (424) was significantly lower in the 
osteoporotic women as compared to the controls representing a less marked nocturnal 
peak. The maximum and mean percentage change in PTH concentration overnight 
increased significantly following GH administration indicating restoration of the nocturnal 
peak.
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Figure 5.3. Cosinor-derived PTH circadian rhythms in premenopausal women and older 
postmenopausal women with low BMD.
Smooth curved lines respresent best fit cosine curves, straight horizontal lines represent MESORs for each 
group and the vertical arrows mark the acrophase. Significant circadian rhythms were demonstrated for for 
both groups with differences in MESOR, acrophase and amplitude. The MESOR was highest in the 
postmenopausal women with alterations to the rhythm that may be contributory to bone loss.
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Figure 5.4. Cosinor-derived PTH circadian rhythms in older postmenopausal women with low 
BMD, prior to and 6 months after GH administration.
Smooth curved lines respresent best fit cosine curves, straight horizontal lines represent MESORs and 
the vertical arrows mark the acrophase. Significant circadian rhythms were demonstrated at both time 
points with a decrease in MESOR following GH administration.
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Arrows represent the acrophase in degrees.
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5.4. Discussion
Postmenopausal women with osteoporosis have lower circulating IGF-1 concentration with 
higher 24-hour mean PTH and lower NcAMP concentration compared with healthy 
premenopasual women with normal BMD. GH administration resulted in increased IGF-1 
concentration, decreased PTH concentration and increased NcAMP. GH administration 
also resulted in an increase in l,25(OH)2D, serum ACa, serum P04, TmPCVGFR and 
biochemical markers of bone turnover with a greater percentage increase in markers of 
bone formation than resorption. Our findings indicate a decrease in target organ sensitivity 
to PTH in postmenopausal women with osteoporosis that increased following GH 
administration. GH administration restored the circadian rhythm of PTH which was altered 
in osteoporotic women.
Changes in PTH and bone metabolism in postmenopausal women with osteoporosis (53-
55) have previously been mainly attributed to oestrogen deficiency following the
menopause, diminished response to vitamin D and to aging itself (316-323). GH effects on
PTH in osteoporosis have only been studied in the short term and with the co-
administration of other calciotropic agents with variable results including decreased (388),
unchanged (136, 388) or increased concentration (250) attributed to increased bone
turnover and enhanced mobilisation of skeletal Ca or increased Ca absorption (136).
Previous studies have not measured NcAMP, which reflects the activity of PTH in both
physiological and pathophysiological states and is a reliable index of PTH function (50).
Since NcAMP excretion parallels changes in PTH secretion (252), the reciprocal increase
in NcAMP excretion with decreasing PTH concentration, observed in our study indicates
increased renal sensitivity to the effects of PTH following GH administration. The
observed decrease in NcAMP back to baseline levels at 12 months may be a reflection of
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the mean GH dose decrease at 12 months. However, the significantly lower PTH 
concentration at 12 months compared to baseline in the presence of a NcAMP 
concentration similar to baseline still suggests an improvement in PTH sensitivity having 
achieved a new equilibrium. PTH demonstrated a sustained increase between 1400-2300 h 
with a reduced nocturnal rise in osteoporotic women as previously demonstrated (66). 
Following GH administration the PTH secretory pattern changed significantly with 
restoration to a rhythm resembling that similar to healthy control subjects (58, 67, 252) 
supporting a role for GH in regulating PTH secretory rhythm.
l,25(OH)2D.and.Ca absorption decrease with aging and the normal increase in l,25(OH)2D 
in response to infusions of PTH is blunted possibly due to decreased renal 25(OH)D la- 
hydroxylase sensitivity to PTH (343). It has also been suggested that women with 
osteoporosis have a defect in renal Ca conservation (358) and the higher urine Ca excretion 
in association with the relatively higher PTH concentration in our subjects suggests renal 
resistance to the effects of PTH may contribute to this. Although the concentrations of 
25(OH)D were similar in both groups studied, they were in the low normal range and this 
may have affected PTH secretion. The initial increase in circulating Ca with no change in 
urine Ca excretion following GH administration may partly reflect increased renal 
sensitivity to PTH resulting in renal Ca reabsorption as a direct effect of PTH (425). A 
possible increase in 1-oc hydroxylase activity resulting in increased l,25(OH)2D production 
(136, 426, 427) and subsequent Ca absorption may also have contributed (196). The 
simultaneous increase in urine Ca excretion probably reflects renal regulation of the higher 
filtered Ca load. By 12 months however the circulating Ca and renal Ca excretion achieve 
equilibrium possibly with increased Ca utilization for bone matrix formation. PO4 levels 
have been shown to increase or remain unchanged in aging postmenopausal women with a 
negative relationship between PO4 and vitamin D. In our osteoporotic subjects with normal
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vitamin D concentrations we found a lower circulating PO4 concentration associated with a 
marginally lower TmPCU/GFR as compared to controls although the difference was not 
statistically significant. An initial increase in both the TmPCVGFR and serum PO4 
concentration was observed following GH administration possibly as a result of a direct 
antiphosphaturic effect of GH/IGF-1 (199, 200) and increased l,25(OH)2D activity (131, 
157). Urine PO4 excretion also increased in parallel with increasing serum PO4 and 
therefore a higher filtered PO4 load before a new equilibrium was established at 12 months 
when circulating PO4 and TmPCVGFR reached a plateau and PO4 excretion began to 
decrease. Increased phosphaturia could also be a reflection of the change in renal 
sensitivity to PTH during GH therapy but clearly the dominant effect of these hormones on 
PO4 is varying with time.
GH administration to osteoporotic patients simultaneously increases markers of both bone 
formation and resolution and thus no increase in BMD is seen in the short term but BMD 
increases following prolonged GH administration (388). Our data confirms a simultaneous 
increase in bone resorption and formation with the increase in bone formation markers 
becoming significantly higher than resorption only by 6 months, possibly explaining the 
delay in increase in BMD following GH administration. The sequence of changes in bone 
turnover markers is different from the response to exogenously administered fixed dose 
PTH which results in an early increase in bone formation markers preceding any increase 
in resorption by about a month. The apparent difference may be a result of several 
individual factors or more likely a combination of these factors. This may include the 
gradual increase in GH dose, the subsequent gradual increase in circulating GH/IGF-1 
concentrations, paracrine and autocrine effects of IGF-1 and other growth factors in the 
bone microenvironment, an increase in bone cell sensitivity to endogenous PTH and 
changes in bone cell responsiveness to changes in the circadian rhythm of endogenous 
PTH.
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In conclusion, our results show that lower GH and IGF-1 concentration are associated with
target organ insensitivity to the effects of PTH and abnormal PTH circadian rhythm in 
postmenopausal women with osteoporosis. GH administration restores PTH sensitivity and 
PTH rhythm with subsequent changes in bone turnover, Ca and PO4 metabolism resulting 
in positive bone balance contributing to the delayed increase in bone density demonstrated 
in previous studies.
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Chapter 6
The Putative Role of Osteoprotegerin in Mediating
the Effects of Parathyroid Hormone Circadian
Rhythm in Postmenopausal Women
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6.1. Introduction
Osteoclast resorptive activity demonstrates circadian rhythmicity and is controlled by 
various endocrine hormones and cytokine factors. PTH is one of the most important of 
these systemic regulators, controlling bone mineral homeostasis. PTH circadian 
rhythmicity is well established in healthy individuals (58, 70, 72, 81, 84) and there is 
increasing evidence that fluctuations in PTH secretion may have an important effect in 
governing normal bone health, bone turnover and bone remodelling. The nocturnal rise in 
PTH secretion is blunted in osteoporotic women (66) and PTH circadian rhythm is lost in 
primary hyperparathyroidism and returns following parathyroid surgery (59). PTH rhythm 
abnormalities have also been demonstrated in adult GH deficient patients who have a high 
incidence of osteoporosis (51, 91). PTH has a concentration and duration dependent 
biphasic effect, and can induce opposing responses resulting in both net bone loss and net 
bone formation (428-432) and the manipulation of the PTH rhythm presents an important 
therapeutic possibility for the treatment of osteoporosis by affecting bone turnover (428). 
At a cellular’ level the effect of PTH on bone turnover is mediated by the production of 
factors from osteoblasts that target osteoclast activity (433-437). The recent discovery of 
OPG and RANKL as the fundamental factors controlling bone turnover has significantly 
advanced the understanding of the processes involved in osteoclastogenesis and bone 
remodeling (433-437). Bone remodelling requires the synthesis of bone matrix by 
osteoblasts along with coordinated resorption by osteoclasts. This process is controlled by 
osteoblasts through the expression of RANKL and OPG (433-439). OPG acts as a decoy 
receptor for RANKL and prevents osteoclastogenesis and bone resorption by inhibiting the 
signals induced by RANKL-RANK interaction (434, 435) and has recently been shown to 
demonstrate a possible circasemidian rhythm in healthy subjects (440).
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Subcutaneous administration of human PTH (1-38) peptide has been shown to induce a 
rapid and transient decrease in OPG mRNA in both metaphyseal and diaphyseal bone of 
rats (441). In animal osteoblast cell culture, PTH stimulates RANKL and suppresses OPG 
expression (441-444). A negative association between OPG and PTH concentrations has 
been demonstrated in men who are over 40 (445) and human PTH (1-34) administered to 
postmenopausal women with glucocorticoid induced osteoporosis decreases the circulating 
concentration of OPG and increases RANKL (446). Animal and human studies have also 
shown the importance of intermittent PTH injections in increasing trabecular bone mass, 
whereas continuous PTH infusions favor bone resorption (63-65). The catabolic effect of 
continuous administration of human PTH (1-38) is associated with inhibited OPG 
production (429).
The circadian rhythm of PTH correlates significantly with the circadian rhythms of bone 
resorption marker, pCTX (51) but the factors mediating the rhythm related effect are still 
unexplained. The recent demonstration of the circasemidian rhythm of OPG raises the 
possibility of this as a putative pathway mediating this effect. We have investigated the 
dynamic relationship between circulating PTH, OPG and PCTX over a 24 h period in 
premenopausal women, postmenopausal women and elderly men.
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6.2. Subjects and Methods
6.2.1. Patients and Controls
Subjects were recruited from hospital personnel and from a database of volunteers willing 
to participate in medical research. Eighteen subjects were recruited for the study, six 
healthy premenopausal women (mean age 30.2 ± 2.2 years), six healthy postmenopausal 
non-osteoporotic elderly women (mean age 68.2 ±2.6 years) and six healthy elderly men 
(mean age 68.2 ± 2.3 years).
6.2.2. Methods
Study visits occurred as documented in section 4.2.3. The local ethics committee approved 
the study, and written informed consent was obtained from each patient before recruitment.
6.2.3. Bone Mineral Density
All subjects underwent bone densitometric evaluation as described in section 3.4.Mean 
age, LS (L2 - L4) and FN T-score are summarized in Table 6.1.
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Table 6.1 Characteristics of Study Population
Age
(years) T-Score
Lumbar Spine 
(L2-L4) Femoral Neck
Healthy Elderly Men 68.17 1.08 -0.02
(n=6)
+ SEM 1.91 0.84 0.32
Premenopausal Women 30.17 0.77 0.80
(n=6)
± SEM 2.17 0.36 0.46
Postmenopausal Women 68.17 1.22 1.27
(n=6)
± SEM 2.12 0.24 0.25
6.2.4. Biochemistry
PTH, OPG and (3CTX were measured on hourly samples using methods as described in 
section 3.2.
6.2.5. Statistical Analysis
PTH, OPG and (3CTX circadian rhythms were assessed as described in section 3.3.3. 
Following the confirmation of concerted circadian rhythms further analysis of the more 
extensively studied PTH rhythm was performed as the next step as described in section
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3.3.3. Changes in OPG and (3CTX concentration were then analysed during corresponding 
time periods in relation to the changes in PTH circadian rhythm.
Cross-correlation analysis was performed to determine the relationships between the 24 h 
profiles of PTH, OPG and (3CTX as described in section 3.3.4.
The differences between groups were determined using ANOVA for repeated measures 
taking into account the 25 measurements for each of the 6 individuals in each group. 
Repeated measures ANOYA assumes normally distributed errors, equal variances and 
sphericity. The Kolmogorov-Smirnov test was used to confirm normal distribution and 
Levenes’s test for equality of variances. Mauchly’s test indicated that the sphericity 
assumption was violated and degrees of freedom were corrected using Greenhouse-Geisser 
estimates of sphericity (£=0.62). The between group comparisons of circadian parameters 
however was performed with n=6 values one for each of the individuals in each group, 
using students t-test for unpahed data. Significant differences are highlighted (*) in Table 
6.2. This comparison is subject to type 2 error given the limited number of individuals in 
the study and the values of circadian parameters presented in Table 6.2 are MESOR, 
amplitude and acrophase from the population mean cosinor analysis (CHRONOLAB 3) for 
the analytes in all 3 groups. Values are expressed as the mean ± SEM. p<0.05 was 
considered significant.
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6.3. Results
6.3.1. 24-hour Mean Concentrations
6.3.I.I. PTH
The difference in 24-h mean PTH concentrations between premenopausal women (4.7 ± 
0.1 pmol/L) and elderly men (5.4 ±0.1 pmol/L) approached significance with p=0.08. 
PTH concentration was highest in postmenopausal women (5.8 ±0.1 pmol/L) and was 
significantly higher than in the premenopausal women and elderly men (p<0,001).
6.3.1.2. Osteoprotegerin
24-h mean OPG concentration was significantly higher in the elderly men as compared to 
the premenopausal women (4.1 ± 0.1 vs. 3.7 ± 0.1 pmol/L; p<0.001). Concentrations were 
highest in the postmenopausal women (4.8 ± 0.1 pmol/L; p<0.001 when compared to 
premenopausal women and elderly men).
6.3.1.3. pCTX
24-h mean (3CTX concentration was significantly higher in the elderly men as compared to 
premenopausal women (0.21 ± 0.02 vs. 0.14 ± 0.03 ^g/L; pcO.001). pCTX concentrations 
were highest in postmenopausal women (0.33 ± 0.03 /ig/L; p<0.001 when compared to 
premenopausal women and elderly men).
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6.3.2. Circadian Rhythm Analysis
Individual and population mean cosinor analyses demonstrated significant circadian 
rhythms for PTH (p<0.05), OPG (p<0.05) and (3CTX (pcO.OOl) in all patients. Cosinor- 
derived population mean circadian rhythms of OPG, PTH and |3CTX are presented in 
Figure 6.1 and population mean parameters for OPG are shown in Table 6.2. The 
individual cosinor parameters are shown in Table 6.3.
6.3.2.I. PTH
Although the circadian rhythm of PTH was maintained in all groups we observed an initial 
increase in PTH concentration beginning at 1600 h (Individual range: 1400 h to 1700 h) 
followed by a later increase beginning at 2400 h (Individual range: 2200 h to 2400 h) in 
premenopausal women, consistent with previous reports in healthy subjects (6). Elderly 
men also demonstrated a PTH increase beginning at 1700 h (individual range: 1400 h to 
1700 h) followed by a second increase beginning at 0100 h (individual range: 2400 h to 
0200 h). To further highlight the differences in secretory pattern between groups, we 
compared the mean percent nocturnal increase from 1600 h [value at each time point-1600 
h concentration)/1600 h concentration X 100] between 1600 h and 2400 h (times of onset 
of the PTH peaks in young, premenopausal, healthy women) and 2400 h and 0800 h (end 
of overnight fast) (51, 91) and no significant difference between men and premenopausal 
women was observed (1600 h-2400 h 7 ± 2% vs. 6 ± 2% ; p=0.4) (2400 h-0800 h 16 ± 2% 
vs. 11 ±2%;p=0.7).
A single sustained increase in PTH secretion between 1600 h and 0800 h was observed in 
the postmenopausal women. The percent increase in PTH secretion between 1600 h and
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2400 h was 14 ± 2% in postmenopausal women and was significantly higher as compared 
to premenopausal women (7 ± 2%; p<0.05). No significant difference in mean PTH 
percent increase was observed between 2400 h to 0800 h when postmenopausal women 
(15 ± 2%) were compared with premenopausal women (16 ± 2%; p=0.7).
6.3.2.2. Osteoprotegerin
In all subjects, the circadian rhythm of OPG secretion was characterized by higher day 
time concentrations and a nocturnal decrease. Time of onset of OPG decrease was defined 
as the time of first occurrence of at least 3 consecutive samples lower than the mean levels 
obtained between 0800 h and 1400 h by more than 1 SD. The nocturnal decrease began at 
1800 h in premenopausal women (individual range: 1500 h to 1900 h), 1600 h in elderly 
men (individual range: 1500 h to 1900 h) and 1600 h in postmenopausal women 
(individual range: 1600 h to 1800 h). We calculated the percent nocturnal decrease in OPG 
between 1600 h and 2400 h (time period during which significant changes in PTH 
secretion were observed). A greater percent decrease [(value at each time point-1600 h 
concentration)/1600 h concentration X 100] in nocturnal OPG secretion was observed in 
the postmenopausal women (15 ± 2%) compared to the premenopausal women (2 ± 2%; 
p<0.01) and the men (7 ± 2%; p<0.05) between 1600 h and 2400 h. The percent decrease 
was also greater between 2400 h to 0800 h in post menopausal women as (23 ± 2%) 
compared to the premenopausal women (3 ± 2%; p<0.01) and the elderly men (6 ± 2%; 
p<0.01). No significant difference was observed between the men and premenopausal 
women.
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6.3.2.3. pCTX
PCTX concentrations demonstrated a nocturnal increase beginning at 2100 h in 
premenopausal women and men (individual range: 2000 h to 2200 h) and at 2000 h in 
postmenopausal women (individual range: 2100 h to 2200 h). The percent increase in 
PCTX concentration between 1600 h and 2400 h in postmenopausal women (58 ± 8%) was 
higher than in premenopausal women (16 ± 8%; p<0.05) and elderly men (19 ± 8%; 
p<0.05) with no significant difference seen between premenopausal women and elderly 
men. The percent increase in pCTX concentration between 1600 h and 0800 h was higher 
in postmenopausal women (103 ± 12%) as compared to premenopausal women (57 ± 12%; 
p<0.05) and elderly men (60±12%; p<0.05).
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Table 6.2. Mean Circadian Rhythm Parameters of OPG, PTH and pCTX
Parameter OPG PTH (1-84) pCTX
Healthy Elderly Men (n=6)
Mesor
Amplitude
Time at peak (h)
4.08 ± 0.08 pmol/L
0.30 + 0.01 pmol/L
1205 (1045- 1325)
5.39 + 0.1 pmol/L
0.44 + 0.01 pmol/L
0015 (2305-0125)
0.21+ 0.01 pg/L*
0.10+ 0.01 pg/L*
0311 (0243-0339)
Statistic significant p < 0.05 p<0.01 p< 0.001
Premenopausal Women (n=6)
Mesor
Amplitude
Time at peak (h)
3.66 + 0.03 pmol/L
0.19 ± 0.01 pmol/L
1150(1025- 1315)
4.73 + 0.08 pmol/L
0.40 + 0.01 pmol/L
0250 (0130-0410)
0.14 ± 0.01 pg/L*
0.06 ± O.OOlpg/L*
0330 (0300-0400)
Statistic significant p < 0.002 p < 0.006 p< 0.001
Postmenopausal Women (n=6)
Mesor
Amplitude
Time at peak (h)
4.74 + 0.06 pmol/L
0.57 ± 0.01 pmol/L
1430(1335 - 1525)
5.83 ± 0.06 pmol/L
0.47 ± 0.01 pmol/L
2350 (2300 - 0040)
0.36 + O.Olpg/L*
0.16 ± O.OOlpg/L*
0235 (0213-0257)
Statistic significant p < 0.001 p < 0.001 p< 0.001
Values are expressed as mean ±SEM, and range is presented in parentheses.
p<0.05 compared to other 2 groups
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Table 6.3. Circadian Rhythm Parameters of OPG in Individual Subjects
MESOR Amplitude Acrophase p-value
(pmol/L) (pmol/L) (h)
Healthy Elderly Men (n=6)
1 2.61 ±0.13 0.27 ± 0.02 1135 <0.05
2 4.71+0.23 0.23 ± 0.02 1045 <0.05
3 5.56 ±0.14 0.38± 0.02 1325 <0.01
4 2.62 ±0.14 0.42± 0.02 1222 <0.05
5 4.34 ± 0.09 0.41± 0.02 1204 <0.001
6 4.52 ±0.41 0.51± 0.03 1240 <0.05
Premenopausal Women (n=6)
1 3.21 ±0.05 0.14± 0.01 1236 <0.01
2 3.31 ±0.04 0.14± 0.01 1025 <0.05
3 6.25 ±0.16 0.52± 0.03 1124 <0.05
4 3.40 ±0.05 0.24± 0.02 0946 <0.05
5 3.67 ± 0.08 0.39± 0.02 1254 <0.01
6 2.05 ± 0.05 0.23± 0.01 1315 <0,001
Postmenopausal Women (n=6)
1 4.74 ±0.15 0.49± 0.02 1344 <0.05
2 4.90 ±0.17 0.49± 0.02 1458 <0.05
3 4.05 ± 0.26 0.53± 0.02 1510 <0.01
4 4.23 ±0.14 0.16± 0.01 1525 <0.05
5 5.80 ±0.15 0.48± 0.02 1242 <0.001
6 4.29 ±0.12 0.49± 0.02 1335 <0.01
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6.3.3. Cross-correlation Analysis
Secretory patterns of PTH and OPG were inversely related and mirrored each other during 
a 24 h period (Figure 6.2). Maximal negative correlation between PTH and OPG was 
observed when PTH changes preceded OPG changes in the opposite direction by 2 hours 
in premenopausal women and elderly men (r = -0.5). A shift in maximum negative 
correlation between PTH and OPG rhythms was observed in postmenopausal women to 0 
lags (r - -0.6) suggesting that changes in PTH and OPG occurred at the same time in 
opposite directions. Maximum negative cross correlation between OPG and (3CTX was 
observed when OPG changes preceded |3CTX changes by 3 hours in premenopausal 
women (r = -0.6) and men (r = -0.6) and 2 hours in postmenopausal women (r = -0.7). PTH 
and (3CTX demonstrated a positive correlation (r = 0.7) with a constant lag time of 2 hours 
in all 3 groups. Cross correlation with log transformed values confirmed these findings.
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6.4. Discussion
Changes in hormonal concentrations are important for physiological and 
pathophysiological effects (447, 448). Circadian rhythms are known to exist for bone 
turnover and bone mineral metabolism and can be altered by changes in PTH circadian 
rhythm (66, 72, 81, 84, 449, 450). Intermittent PTH injections increase trabecular bone 
mass, whereas continuous PTH infusion favors bone resorption with inhibited OPG 
production (63-65, 429). The significant differences in the circadian rhythms, temporal 
interactions and concentrations of PTH, OPG and PCTX secretion we observed when 
postmenopausal women were compared with elderly men and premenopausal women 
suggest that the rhythmicity of osteoclast activity and the increased osteoclast activity in 
postmenopausal women may be mediated by this pathway.
A circasemidian rather than circadian rhythm for OPG has been reported with a bimodal 
variation in a mixed group of 9 subjects (mean age of 32.5 ± 7.8 years). The findings were 
based on 4-homiy samples and a circadian rhythm could not be demonstrated using cosinor 
analysis due to the limited number of samples, and results were based on data expressed as 
percentages of the arithmetic mean of each time series (440). Our data confirms a circadian 
rhythm for OPG with a pattern different to that reported previously. The difference in age 
and gender of the groups studied, as well as the difference in OPG assay used may have 
been contributory factors, but more importantly cosinor analysis is dependent on the 
sampling frequency and bio-kinetic properties of the analyte. Despite its short half-life 
(451) the circadian characteristics of PTH have been demonstrated with hourly sampling 
in this study but the characteristics can not however be demonstrated with samples greater 
than 2 hours apart (452). Thus increased sampling frequency provides a more accurate 
representation of circadian rhythmicity. The half-life of OPG has been shown to be
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approximately 20 minutes in rats (435) but no human data is available. All studies 
measuring circulating OPG are also limited by the multiplicity of its extra-skeletal sources 
and the possible discrepancy between circulating concentrations and concentrations in the 
bone micro-environment. Despite these factors the increased sampling frequency in our 
study results in a more accurate representation of emulating OPG concentrations over a 
24-h period.
The profiles of OPG and PTH in our patients were inversely related and mirrored each 
other suggesting that the expression of PTH and OPG may be linked to common rhythm 
generating or common regulatory factors and that fluctuations in PTH concentration over a 
24 hour period may directly or indirectly regulate OPG production, consistent with the 
known suppressive effect of PTH on OPG production in vitro and in vivo. PTH (1-34) 
suppresses OPG and stimulates RANKL both in vitro and in vivo and an inverse 
correlation between PTH and OPG has been established (429, 441-444, 446, 453). 
Pharmacological administration of human PTH (1-34) decreased circulating OPG levels in 
postmenopausal women with glucocorticoid induced osteoporosis (446) and PTH has also 
been shown to negatively correlate with serum OPG levels in men beyond 40 years after 
adjustment for age and body weight (445).
Osteoclast activity is regulated via cross-talk between osteoblasts and osteoclasts mediated 
by OPG and RANKL and blocking RANKL signaling with OPG is able to block the pro- 
resorptive effects of PTH. Although controversial, PTH may also directly affect osteoclast 
activity via PTH receptors (116, 454). The maximum correlation between PTH and PCTX 
remained constant in all 3 groups but in postmenopausal women the temporal relationship 
between PTH and OPG and OPG and (3CTX was altered. It is possible that the constant 
time lag between PTH and (3CTX is a reflection of the direct effect of PTH on osteoclasts
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which remains unaltered. The altered temporal relationship between PTH, OPG and |3CTX 
may reflect changes in the indirect effect of PTH on osteoclasts via osteoblast cross-talk. In 
vitro, PTH (1-34) administration suppresses OPG and stimulates RANKL gene expression 
within 1 hour (429, 441-444, 446, 453) and in vivo subcutaneous administration of a single 
injection of PTH (1-38) at 80 pg/kg has been shown to induce a rapid and transient 
decrease in OPG mRNA in both metaphyseal and diaphyseal bone of rats that is evident by 
1 hour (441). Our data indicate that changes in OPG concentration follow changes in PTH 
by two hours in premenopausal women and in healthy elderly men. Observational data 
must be interpreted with caution as they do not entirely reflect data following 
pharmacological administration. In postmenopausal women the temporal relationship 
between PTH and OPG was altered, with changes in PTH and OPG occurring 
concurrently. The altered effect of PTH on OPG may be a consequence of the altered 
hormonal milieu, including the lack of oestrogen following the menopause and/or the 
declining GH and IGF-1 concentrations with increasing age (277-283) either interfering 
with the effect of PTH on OPG production by osteoblasts or affecting osteoblast 
production of OPG directly and thus altering the temporal relationship. The 3 hour delay 
between changes in OPG and [3CTX probably reflects a separate osteoblast mediated 
component of osteoclast activity which is altered in postmenopausal women via similar 
mechanisms. These temporal alterations may contribute to the significantly greater 
nocturnal decrease in OPG concentrations and increased osteoclast activity in 
postmenopausal women. Interpretation of the temporal relationships reported in our study 
is limited by the cross-sectional design of the study and dependency of the statistical 
technique on sampling frequency of the analytes. Further interventional studies designed to 
induce shifts in the analyte concentrations and more frequent sampling would be required 
to confirm the exact time taken for PTH to alter circulating OPG and (3CTX in these 
different patient groups.
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OPG is a major biological factor that inhibits osteoclast differentiation, formation and 
function (434, 435, 455, 456) and circulating OPG concentrations are altered in conditions 
of abnormal bone remodeling (423, 433, 435, 439, 457-461). Results from previous studies 
using single time point sampling methodology have been inconsistent and while some 
studies have demonstrated a negative correlation between circulating OPG and bone 
resorption markers (457, 459, 461) others have not (462-466). The negative correlation of 
serum OPG concentrations with BMD has also been reported by some (460, 467, 468) but 
not others (462, 464-466), High serum OPG concentrations have been observed in patients 
with Paget’s disease (457) but not from patients with severe osteolysis (469). These 
discordant results may reflect the single time point (fasting sample) methodology in sample 
collection. Our observation that OPG is subject to diurnal variation may help explain some 
of these inconsistencies. Future studies on circulating OPG must take into consideration 
this variability.
The majority of data currently supports higher circulating OPG in conditions where bone 
resorption predominates over bone formation. Higher OPG concentrations have been 
reported in elderly and postmenopausal women with and without osteoporosis (458-461, 
470, 471) and our findings are in keeping with this. Because serum OPG was positively 
correlated with biochemical markers of bone resorption in these studies this was thought to 
be a somewhat ineffective counter-regulatory mechanism to prevent further bone loss 
(439). Alternative explanations are that OPG clearance is decreased in the elderly or there 
is enhanced release from bone with aging due to micro fractures. Because of the 
contradiction between local OPG levels, which decrease with aging, and the unambiguous 
findings of increased circulating OPG serum levels with aging, it is unclear' whether 
circulating OPG adequately reflects local OPG production within the bone
176
microenvironment, especially during aging (445). Several reports have also established an 
inverse relationship between OPG and bone resorption markers (423, 461, 472). A 
significantly higher mean nocturnal percent decline in OPG may result in increased 
nocturnal bone resorptive activity by osteoclasts as observed in our postmenopausal 
subjects and explain the apparent contradiction and ineffectiveness of higher fasting or 24- 
h mean OPG concentration in postmenopausal women. The dynamic change in OPG 
concentration we have observed may be the important regulatory factor for osteoclast 
function rather than absolute circulating values.
OPG activity goes hand in hand with RANKL activity with the ratio between the two being 
more relevant to bone cellular activity than absolute values of either taken individually. 
Most RANKL activity is provided by its expression on the osteoblast cell surface. Current 
RANKL assays are problematic and not sufficiently sensitive as they measure soluble 
RANKL that is unstable, is degraded rapidly or binds to OPG to form large stable 
conglomerates (473) . RANKL profiles were investigated in several individuals from each 
group using a current available assay (ELISA measurement provided by Biomedica, 
Oxford Biosystems, UK) but the concentrations of RANKL obtained were ail close or 
below the assay detection limit and no statistically significant variability was observed and 
this data was not included in the study. Since OPG is a decoy receptor for RANKL and 
they have an inverse relationship, it is possible that total RANKL may demonstrate diurnal 
variation opposite to that of OPG but similar to PTH. Future studies with more sensitive 
RANKL assays would be required to confirm or refute this hypothesis.
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In conclusion, we have confirmed a significant circadian rhythm for OPG in different 
subject groups and propose that altered OPG circadian rhythm may be an additional factor 
contributing to postmenopausal bone loss. The circadian rhythm of PTH is recognized as a 
significant regulator of bone turnover and the rhythm mediated effect may be, at least in 
part, mediated by the rhythm of OPG. Significantly greater nocturnal decline in circulating 
OPG in postmenopausal women may in paid alter the circadian pattern of osteoclast 
activity on a daily basis resulting in higher nocturnal resorption and net bone loss. The rate 
of change of OPG concentration could contribute to the rate of bone resorption over and 
above the absolute circulating OPG concentration. Manipulation of the endogenous rhythm 
of OPG presents another possible therapeutic target for osteoporosis and our findings 
warrant future studies aimed at identifying factors that may be utilized to modify the 
circadian secretion of OPG to prevent bone loss.
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Chapter 7 
Conclusions
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The studies in this thesis have further defined the role of the GH/IGF-1 axis, target-organ 
sensitivity to PTH and PTH secretory rhythm in the pathogenesis of age related and 
postmenopausal osteoporosis. The findings also highlight the distinct differences in the 
patterns of bone loss and underlying mechanisms between men and women.
Various lines of investigation have suggested that GH plays a central role in the 
development of primary osteoporosis. Advancing age is associated with a reduction in GH 
secretion and so it has been proposed that a relative GH deficiency in older patients may 
underlie the development of age-related osteoporosis (280, 290). A relative GH deficiency 
also occurs following the menopause. The presence of oestrogen is required for GH 
secretion, thereby providing a mechanism by which oestrogen regulates bone turnover 
indirectly through its effect on the GH/IGF-1 axis (290, 293, 474, 475). Therefore, a 
reduction in GH secretion in postmenopausal women may contribute to the development of 
osteoporosis (293, 474). Despite these facts previous attempts to administer GH therapy in 
primary osteoporosis have been disappointing. Markers of bone turnover have been shown 
to increase following the administration of GH to postmenopausal women but with poor 
tolerability and little benefit in terms of improvement in BMD (378, 384, 385). More 
recently, however, a 5 year study reported a 15 % increase in BMD following low dose GH 
therapy, with few side effects reported (388). Despite these findings the underlying 
mechanisms have not been fully investigated or understood.
The role of insensitivity to PTH and abnormal PTH rhythm has been established in the 
AGHD model of osteoporosis (51, 91) and the studies in this thesis help define a role for 
insensitivity to PTH and abnormal PTH rhythm in the development of osteoporosis in 
postmenopausal women. PTH sensitivity improves and PTH rhythm is restored following 
GHR in patients with AGHD. These mechanisms contribute to the improvement in bone
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turnover and BMD in GH replaced AGHD patients (91). The data presented in this thesis 
provides evidence that PTH insensitivity and abnormal PTH rhythm contribute to the 
development of postmenopausal osteoporosis. GH administration to postmenopausal 
women results in an increase in IGF-1, improved PTH sensitivity and restoration of PTH 
rhythm in a manner similar to that seen in AGHD patients treated with GH. These changes 
are associated with significant improvements in bone metabolism and turnover that would 
result in increased BMD. Furthermore titrated GH doses that demonstrated benefit were 
well tolerated.
Older men also have lower IGF -1 concentrations with decreased target-organ sensitivity to 
the effects of PTH. The degree of PTH insensitivity is greater in older men with low BMD. 
Normal PTH circadian rhythmicity is lost and bone resorption is increased in older men 
with low BMD but not in older men with normal BMD. Primary osteoporosis in men is 
less well studied and various etiological mechanisms have been suggested. We propose 
that the age related decline in GH and IGF-1, modified by the age related decline in bio- 
available gonadal hormones results in PTH resistance and abnormal PTH rhythm. Both of 
these mechanisms contribute to the development of bone loss in older men with low BMD.
Although the importance of the secretory rhythm of PTH is well documented (58, 70, 72, 
81, 84), the mechanisms by which the altered secretory rhythm increases bone resorption 
and bone loss is unclear. Our findings suggest that OPG may mediate the rhythm 
dependent effect of PTH on bone turnover. Loss of normal PTH circadian rhythmicity in 
postmenopausal is associated with a greater nocturnal decline in circulating OPG. This in 
turn may account for the nocturnal increase in bone resorption seen in postmenopausal 
women and hence postmenopausal bone loss.
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The development of effective treatments for postmenopausal osteoporosis is particularly 
important in view of the decline in use of oestrogen therapy following the announcement 
of detrimental effects of HRT in the Women’s Health Initiative study (476). 
Bisphosphonates currently represent standard treatment of postmenopausal osteoporosis 
but increases in BMD are limited by the reduction in bone remodelling space occurring as 
a consequence of reduction in bone resorption (477).
In women with postmenopausal osteoporosis, daily subcutaneous injections of full length 
parathormone (1-84 PTH) and teriparatide (the 1-34 N-terminal fragment of PTH) showed 
the largest increases in BMD repotted to date for any treatment of osteoporosis, 
accompanied by an important reduction of the risk of new vertebral fractures (478, 479). 
Teriparatide was shown to reduce the risk of vertebral and non-vertebral but not hip 
fractures in postmenopausal and glucocorticoid-induced osteoporosis (479, 480). Although 
the safety and efficacy of teriparatide have been studied beyond two years of treatment, the 
generally approved duration of therapy is limited to two years.
While therapeutic alternatives are available for inhibiting bone resorption, options are 
much more limited with regard to bone anabolic substances. There is a need for new bone 
active substances aimed at restoring quantitatively and qualitatively normal bone. The 
safety profile of most bone active substances is at least partially known, but there is 
considerable potential for improvement (osteonecrosis of the jaw, atypical fractures, 
interactions with the immune system). Treatment alternatives are needed for patients 
exhibiting or at risk of side-effects. While a relative fracture risk reduction of up to 20%, 
50%, and 70% can be achieved for non-vertebral, hip, and spine fractures, respectively, 
still 30 to 80% of these fractures cannot be prevented. As osteoporosis is a systemic
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disease, there is an obvious need for improving the magnitude of the therapeutic effect at 
all fracture sites. Therefore limitations currently exist with available effective therapies for 
the treatment of primary osteoporosis (481).
Although GH has previously been relegated to a forgotten corner of skeletal anabolics, the 
recent demonstrated benefit in BMD with GH doses that were well tolerated provide some 
room to reconsider the notion that there may still be a role for GH therapy in the 
management of primary osteoporosis. Recent studies using adjunctive therapies with GH in 
AGHD patients have been promising. Similar’ studies in primary osteoporotic patients may 
help achieve better improvements in BMD with GH. An understanding of the intricate 
mechanisms by which GH exerts its anabolic effects is thus essential. It may be possible in 
the future to harness its full potential as a possible anabolic therapeutic modality for 
osteoporosis, a disease for which treatment options are still limited.
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